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ABSTRACT
Background: Diabetic nephropathy (DN) is a renal complication of diabetes and a common cause of
end-stage renal disease (ESRD). DN presents in its earliest stage with low levels of albumin in the
urine (microalbuminuria) and develops into overt albuminuria as the disease progresses. Podocyte
loss due to detachment or apoptosis has a central role in the pathogenesis of DN, but the mechanisms
are  not  fully  understood.  The  studies  in  this  thesis  aimed  to  increase  the  knowledge  of  the
pathophysiological mechanisms and molecular pathways leading to podocyte apoptosis in DN by
studying three molecules that are expressed in podocytes, SH2-domain-containing inositol
polyphosphate 5-phosphate 2 (SHIP2), 3-phosphoinositide-dependent kinase 1 (PDK1) and cyclin-
dependent kinase 2 (CDK2).
Results: Lipid phosphatase SHIP2 was identified as an interaction partner of CD2AP, a protein
known to be involved in the regulation of apoptosis in podocytes. We found that overexpression of
SHIP2 in cultured podocytes reduced the phosphorylation of the major cell survival kinase Akt in
response to insulin and increased apoptosis. We also observed that the expression of SHIP2 was
upregulated in glomeruli of insulin resistant obese Zucker rats prior to the onset of proteinuria,
suggesting a role for SHIP2 in the development of podocyte injury.
In contrast, we found that the expression of PDK1 and CDK2 was downregulated in obese Zucker
rats before they had developed proteinuria. We also observed that treatment of human podocytes with
sera  from  normoalbuminuric  type  1  diabetic  (T1D)  patients  with  high  lipopolysaccharide  (LPS)
activity downregulated the expression of PDK1 and CDK2. LPS treatment of mice in vivo also
reduced PDK1 and CDK2 expression. LPS-induced downregulation of PDK1 and CDK2 was
prevented both in vitro and in vivo by inhibition of the toll-like receptor (TLR) pathway using
immunomodulatory agent GIT27. Knockdown of either PDK1, or CDK2 inhibited antiapoptotic Akt
pathway, stimulated the proapoptotic p38 MAPK pathway and increased podocyte apoptosis.
Conclusions: Given the central role of the PI3K-dependent Akt signaling pathway in regulating cell
survival, our findings suggest that SHIP2, PDK1 and CDK2 regulate apoptosis in podocytes by
modulating the activity of the PI3K-dependent Akt signaling pathway.
11
1. INTRODUCTION
Diabetes is a chronic disease that occurs when the pancreas is no longer able to produce insulin (type
1 diabetes, T1D), or when the body cannot use the insulin it produces (type 2 diabetes, T2D). It is a
global problem that is continuously increasing. T1D is usually caused by an autoimmune destruction
of the insulin-producing beta cells in the pancreas. T2D, that accounts for over 90% of all cases of
diabetes, is a metabolic disorder that is characterized by hyperglycemia in the context of insulin
resistance and relative insulin deficiency (Kumar et al., 2015;Zimmet et al., 2001). According to
International Diabetes Federation (2014), approximately 387 million people were suffering from
diabetes in 2014 and the amount is estimated to increase up to 592 million by 2035. Both T1D and
T2D increase morbidity and mortality due to micro- and macrovascular complications. The
microvascular complications include diabetic nephropathy (DN), retinopathy and neuropathy, and the
macrovascular complications refer to cardiovascular disease, stroke and peripheral vascular disease.
DN, a complication of T1D and T2D, is the most common cause of end-stage renal disease (ESRD)
in patients with diabetes worldwide (Borch-Johnsen and Kreiner, 1987;Zimmet et al., 2001). DN is
associated with increased risk of cardiovascular disease and mortality (Groop et al., 2009;Nathan et
al., 2005). DN is characterized by increased urinary albumin excretion, glomerular hypertrophy,
mesangial expansion, glomerular basement membrane (GBM) thickening, foot process effacement
and podocyte apoptosis (Meyer et al., 1999;Mogensen, 1984;Mogensen and Christensen,
1984;Pagtalunan et al., 1997;Parving et al., 1982;Tervaert et al., 2010;Viberti et al., 1982).
Podocytes are highly specialized epithelial cells covering the glomerular basement membrane (GBM)
with their interdigitating foot processes. Podocytes form the filtration barrier of the glomerular
capillary wall together with the fenestrated endothelial cells and the GBM. Podocyte loss due to
detachment or apoptosis, is one of the key features of progressive glomerulosclerosis. Podocyte loss
has been reported in patients with T1D (Steffes et al., 2001) and T2D with or without DN (Meyer et
al., 1999;Nakamura et al., 2000;Verzola et al., 2007), and Verzola et al. reported glomerular apoptosis
in  the  kidneys  of  patients  with  DN  (Verzola  et  al.,  2007).  In  Pima  Indians  with  T2D,  decreasing
number of podocytes per glomerulus has been shown to be the strongest indicator of the progression
of the renal disease (Meyer et al., 1999).
Several key podocyte proteins essential for glomerular filtration, such as transient receptor potential
cation channel 6 (TRPC6), nephrin and CD2-associated protein (CD2AP), are known to be involved
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in the regulation of apoptosis in podocytes (Asanuma et al., 2007;Huber et al., 2003;Li et al., 2013).
Reactive oxygen species (ROS), transforming growth factor beta (TGF-ß), angiotensin II, and
lipopolysaccharides (LPS)/endotoxins (Binder et al., 1999;Chen et al., 2009;Jia et al., 2008;Li et al.,
2013;Srivastava et al., 2013;Susztak et al., 2006), that are lipid-soluble membrane components of the
gram-negative bacteria, have been shown to induce podocyte injury and apoptosis.
Podocyte apoptosis plays a critical role in the pathogenesis of glomerular diseases. Therefore, analysis
of the molecules involved in the regulation of apoptosis in podocytes is essential to better understand
the pathophysiological mechanisms of diabetic kidney diseases and to be able to prevent podocyte
apoptosis and the progression of diabetic kidney complication. The studies in this thesis were initiated
by characterization of new interaction partners of CD2AP, since CD2AP is known to be involved in
the regulation of apoptosis in podocytes.
We found that SH2-domain-containing inositol polyphosphate 5-phosphate 2 (SHIP2), a molecule
involved in insulin resistance and metabolic syndrome, interacted with CD2AP. Furthermore, SHIP2
was found to be involved in the PI3K-dependent Akt signaling pathway and regulation of podocyte
apoptosis. We also identified that 3-phosphoinositide dependent protein kinase-1 (PDK1), a
serine/threonine kinase that serves as a major regulatory point in Akt signaling, and CDK2, a S-phase
cyclin-dependent kinase, that is regulated by Akt and also activates Akt, are involved in podocyte
apoptosis. These results suggest that SHIP2, PDK1 and CDK2 regulate podocyte apoptosis by
modulating the activity of the PI3K-dependent Akt signaling pathway. Therefore differences in the
expression of these proteins may associate with the development of diabetic kidney diseases.
Modulating the expression or functions of these molecules may provide a concept to prevent podocyte
apoptosis, and could therefore be used as a treatment strategy in preventing the progression of DN.
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2. REVIEW OF THE LITERATURE
2.1. Kidney structure and function
The kidneys are a pair of organs that perform several important functions in the body. They lie behind
the posterior abdominal wall. The primary function of the kidneys is the filtration of plasma to secrete
waste products from the blood into the urine. Kidneys play an essential role in maintaining the
electrolyte, fluid and acid-base balance in the body. They also secrete hormones needed for blood
pressure regulation and red blood cell formation.
Each human kidney has approximately one million nephrons, which are the basic functional units of
the  kidney.  Each  nephron  consists  of  the  glomerulus  and  the  tubulus.  The  glomerulus,  that  is
responsible of the plasma filtration, is a capillary tuft surrounded by Bowman´s capsule located in the
kidney cortex (Figure 1A). The tubular system is formed by the proximal and distal tubule, and the
loop of Henle (Figure 1B).
Close to 180 liters of primary urine is formed daily by the kidney glomeruli. Primary urine is modified
in the tubular system by reabsorption of water and electrolytes so that the daily urinary excretion is
normally 1-1.5 liters (reviewed in Tisher and Madsen, 1991).
Figure 1. Illustration of kidney (A) and nephron (B) anatomy. Modified from Marieb, 2001.
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2.2.  Glomerular filtration barrier
The ultrafiltration of plasma occurs in glomeruli (Figure 2A), where primary urine is filtrated through
the glomerular filtration barrier (GFB) (Figure 2B). Water and small and midsized solutes pass the
GFB, but macromolecules and blood cells are retained in the circulation. Ultrafiltration takes place
between the capillary lumen and the urinary space. GFB is a highly specialized structure forming a
size, charge and shape-selective filter. The barrier consists of three layers, the fenestrated endothelial
cells, glomerular basement membrane (GBM) and highly differentiated glomerular epithelial cells,
podocytes that form the final filter with their slit diaphragms (Haraldsson et al., 2008).
Figure 2. Structure of the glomerulus (A) and the glomerular filtration barrier (B). GMB: glomerular
basement membrane; SD: slit diaphragm. Modified from Komorniczak, 2009 (A) and Suh and Miner,
2013 (B).
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2.2.1. Endothelium
The glomerular endothelial cells line the glomerular capillaries forming the first part of GFB.
Glomerular endothelial cell fenestrations are transcellular holes of 60-100 nm in diameter that are
specialized for filtration of fluid across the cell layer (Haraldsson et al., 2008;Satchell and Braet,
2009).  Glomerular  filtration  rate  is  dependent  on  the  number  and  size  of  the  fenestrations.  The
endothelial cells have charge-selective properties due to the negatively charged glycocalyx, that
provide the first barrier to albumin (Haraldsson et al., 2008;Satchell and Braet, 2009).
2.2.2. Glomerular basement membrane
GBM is a 250-400 nm thick non-cellular layer of the glomerular filtration barrier situated between
endothelial cells and podocytes. GBM is composed of extracellular matrix proteins including type IV
collagen (collagen α3, α4 and α5 chains), laminins, nidogen/entactin and heparin sulfate
proteoglycans, which provide an anionic charge to the GBM and form a meshwork with both size-
and charge-selective properties (Haraldsson et al., 2008;Suh and Miner, 2013).
2.2.3. Podocytes
Podocytes are polarized, terminally differentiated and highly specialized cells that surround the
glomerular capillaries facing the Bowman´s capsule and the primary urine and form the major
component of the glomerular filtration barrier.
2.2.3.1. Slit diaphragm
The podocyte cell body gives rise to major processes that extend to foot processes which are
interconnected with special cell adhesion structures called slit diaphragms (SD).  Rodewald and
Karnowsky (1974) were first to visualize these zipper-like structures with pores almost the same size
as albumin using electron microscopy suggesting that they function as a sieve for plasma proteins
(Rodewald and Karnovsky, 1974).
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2.2.3.2. Podocyte proteins
There are several podocyte proteins, such as nephrin, trancient Receptor Potential Cation Channel 6
(TRPC6), CD2-associated protein (CD2AP) and podocin, known to be essential for glomerular
filtration (Figure 3), that are also involved in the regulation of apoptosis in podocytes. The
involvement of nephrin and CD2AP in podocyte apoptosis is described in more detail in Section 2.5.
Nephrin is the major molecule of the SD (Ruotsalainen et al., 1999). Nephrin is a transmembrane
protein that belongs to the immunoglobin superfamily (Holthofer et al., 1999;Holzman et al.,
1999;Kestila et al., 1998;Ruotsalainen et al., 1999). Nephrin forms the SD framework together with
the Neph-protein family (Neph 1-3) (Barletta et al., 2003;Gerke et al., 2003;Ruotsalainen et al., 1999).
Nephrin is mutated in the human congenital nephrotic syndrome of the Finnish type (CNF) that is a
serious renal disease described already in 1956 (Ahvenainen et al., 1956;Kestila et al., 1998). Nephrin
expression was found to be reduced also in human DN (Doublier et al., 2003). In addition, Li et al.
(2015) demonstrated that nephrin is needed for the maintenance of the SD integrity, as mice with
long-term nephrin knockout showed increase in podocyte apoptosis (Li et al., 2015).
TRPC6 that is also expressed in the SD and known to interact with nephrin (Reiser et al., 2005), was
found to be mutated in focal segmental glomerulosclerosis (FSGS) (Winn et al., 2005). Moller et al.,
(2007) found increased TRPC6 expression in the glomeruli of patients with proteinuric kidney
diseases, such as membranous glomerulonephritis and minimal-change disease (Moller et al., 2007).
Lu et al. (2015) demonstrated that oxygenated podocytes undergo apoptosis due to intracellular
elevation of Ca2+ via TRPC6 (Lu et al., 2015).
CD2AP has also been shown to interact with nephrin (Palmen et al., 2002;Shih et al., 1999;Shih et
al., 2001), and it has been demonstrated that CD2AP also directly interacts with actin (Lehtonen et
al., 2002). Mice lacking CD2AP develop nephrotic syndrome resembling the human disease and die
of renal failure at the age of six to seven weeks. The glomeruli of these mice show podocyte
effacement (Shih et al., 1999) similar to that in the CNF (Patrakka et al., 2000;Smoyer and Mundel,
1998). In addition, mutations in CD2AP have also been shown in human patients with FSGS (Gigante
et al., 2009;Kim et al., 2003).
Podocin, a podocyte-associated protein, has been shown to localize to the podocyte foot process
membrane and to interact with nephrin and CD2AP (Schwarz et al., 2001). Shibata et al., (2005)
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demonstrated reduced expression of podocin in glomeruli of rats with PAN nephrosis (Shibata et al.,
2006). In addition, mutation in podocin induces podocyte injury suggesting that podocin has a role in
podocyte apoptosis (Fan et al., 2009).
In addition to nephrin, TRPC6, CD2AP and podocin, several cytosolic scaffolding molecules, tight
junction proteins etc. together with the membrane proteins contribute to maintaining the structure of
the SD (reviewed in Kawachi et al., 2006;Sampogna and Al-Awqati, 2012).
Figure 3. Schematic presentation of the molecular components of the slit diaphragm. TRPC6:
Trancient Receptor Potential Cation Channel 6; CD2AP: CD2-associated protein. Modified from
Dinga et al., 2015.
2.3. Diabetic Nephropathy
Diabetic nephropathy (DN) is the leading cause of kidney disease in patients starting renal
replacement therapy. DN affects around 40% of type 1 and type 2 diabetic patients (Gross et al.,
2005;Zimmet et al., 2001).
2.3.1. Clinical features of diabetic nephropathy
DN is a progressive kidney disease categorized into stages based on values of albumin excretion rate
(AER): microalbuminuria, macroalbuminuria and proteinuria. Microalbuminuria, the early stage is
characterized by a small increase in AER (30-300 mg/24 h), macroalbuminuria as AER >300 mg/24
h and proteinuria as AER >500 mg/24 h. Macroalbuminuria and proteinuria, latter classically named
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overt DN, take years to develop and are considered as a definition of more advanced disease. In most
cases, macroalbuminuria and proteinuria lead to decreased glomerular filtration rate (GFR) (Reutens
and Atkins, 2011). DN is characterized by progression of microalbuminuria to macroalbuminuria that
may subsequently lead to end-stage renal disease (ESRD). DN is the leading cause of ESRD in Europe
(Kramer et al., 2009).
The increase in AER as a predictor of proteinuria in type 1 (Mogensen and Christensen, 1984;Parving
et al., 1982;Viberti et al., 1982) and type 2 (Mogensen, 1984) diabetic patients, was first described in
the beginning of 1980s. In these studies, it was shown that up to 85% of patients with
microalbuminuria progressed to macroalbuminuria (Mogensen and Christensen, 1984;Viberti et al.,
1982). However, in later studies, the risk of progression has decreased, mostly due to intensive
treatment of hyperglycemia and hypertension (Caramori et al., 2000;Forsblom et al., 1992). Although
considered as a risk factor for macroalbuminuria, microalbuminuria has also been shown to regress
to normoalbuminuria in some patients (Perkins et al., 2003).
2.3.2. Pathology of diabetic nephropathy
DN is characterized by histological and structural changes in the kidney (Figure 4.). The glomerular
classification of DN starts by GBM thickening and mesangial expansion, finally leading to advanced
diabetic glomerulosclerosis (Tervaert et al., 2010). GBM thickening, the main finding of DN (Fioretto
et al., 1995;Osterby, 1972) is a characteristic early change in both type 1 (Mauer et al., 1984;Osterby,
1972) and type 2 diabetic nephropathy (White and Bilous, 2000), but it does not correlate with the
severity of the clinical disease (Mauer et al., 1984), since it remains stable within the duration of the
disease (Fioretto et al., 1995). Mesangial expansion, defined as an increase in extracellular material
in the mesangium, can be divided into mild and severe stages depending on the size of the expanded
mesangial area (Tervaert et al., 2010). Mesangial expansion is a hallmark of both type 1 and type 2
diabetic nephropathy (Mauer et al., 1984;White and Bilous, 2000). Kimmelstiel and Wilson reported
first in 1936 mesangial matrix accumulation as the characteristic histological feature of DN
(Kimmelstiel and Wilson, 1936). They found nodular-shaped intercapillary hyalinous lesions, now
often known as Kimmelstiel-Wilson lesions, as the hallmark of more severe stage of nephropathy
(Hong et al., 2007;Schwartz et al., 1998;Tervaert et al., 2010). Advanced diabetic glomerulosclerosis,
the most severe case of DN, is developed when Kimmelstiel-Wilson lesions finally result in
glomerulosclerosis (Qian et al., 2008).
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Figure 4. Characteristic changes in glomerular filtration barrier during development of diabetic
nephropathy. (A) Normal glomerular filtration barrier. (B) Diabetic kidney. GBM: glomerular
basement membrane; SD: slit diaphragm. Modified from Suh and Miner, 2013.
2.3.3. Mechanisms of diabetic nephropathy
Several factors affect the pathogenesis of DN. For instance age, gender, smoking, hyperglycemia,
elevated blood pressure, hyperlipidemia, hyperfiltration and genetic susceptibility are risk factors
identified in the development of DN (Ayodele et al., 2004;Hovind et al., 2001;Hovind et al.,
2003;Zelmanovitz et al., 2009). Hyperglycemia is one of the major factors contributing to the
development of diabetic kidney disease. Also, the decreased number of podocytes in glomeruli is one
of the strongest predictors of progression of DN (Meyer et al., 1999;Pagtalunan et al., 1997). Renal
biopsy studies in humans have demonstrated that podocytes are functionally and structurally injured
in the early stages of DN (Dalla Vestra et al., 2003).
2.3.3.1. Hyperglycemia
Hyperglycemia is a crucial risk factor in the development of DN. Hyperglycemia induces the
pathologic changes leading to DN, including excessive formation of advanced glycosylation end-
products (AGEs), production of reactive oxygen species (ROS), increased flux through the polyol
pathway and an abnormal activation of protein kinase C (PKC) as a result of increases in glycolysis
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or lipid synthesis (Sheetz and King, 2002). Strict glycemic control can decrease the risk of DN (UK
Prospective Diabetes Study (UKPDS) Group, 1998).
2.3.3.2. Podocyte injury
Podocytes play a critical role in maintaining the structure and function of the glomerular filtration
barrier. Therefore podocyte foot process effacement and the decreased number of podocytes in
glomeruli are the strongest predictors of progression of DN (Toyoda et al., 2007;Weil et al., 2012).
However, understanding the pathophysiological mechanisms that underlie the loss of podocytes in
DN remain limited.
2.3.3.2.1. Podocyte foot process effacement
Podocyte foot process effacement is characteristic of proteinuric renal diseases including DN
(Pagtalunan et al., 1997). Widening of podocyte foot processes has been shown in patients with type
1 diabetes (T1D) and type 2 diabetes (T2D) (Meyer et al., 1999;White et al., 2002). Effacement is
caused by interference with the GBM or the podocyte-GBM interaction, changes in the SD-associated
proteins, abnormalities in the actin cytoskeleton and neutralization of negative cell surface charges
with the apical membrane domain of podocytes (reviewed in (Mundel and Shankland, 2002).
2.3.3.2.2. Podocyte hypertrophy
Mature podocytes do not proliferate under normal conditions, however, in certain diseases such as
HIV nephropathy (Barisoni et al., 1999) and collapsing glomerulopathy (Nagata et al., 1998),
podocytes re-enter the cell cycle and start to proliferate. Since development of clinical nephropathy
is associated with the reduction in the number of podocytes per glomerulus, and total surface area
covered by podocytes does not change, this increase in the surface area must be covered by remaining
podocytes (Pagtalunan et al., 1997). Due to the limited capacity to proliferate, podocytes are largely
dependent on hypertrophy to increase the podocyte mass in the glomeruli (Wiggins et al., 2005).
Under diabetic conditions, as mesangial cells, podocytes also undergo hypertrophic processes
resulting in increased cell size (D'Agati, 1994;Petermann et al., 2002). Petermann et al. (2002) showed
that mechanical stress reduces cell-cycle progression and induces hypertrophy in podocytes in vitro.
Rüster et al. demonstrated that AGE-modified bovine serum albumin induced hypertrophy and injury
in cultured podocytes which can be involved in podocyte loss (Ruster et al., 2008). In addition, Lee
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et al. (2015) suggested recently that podocyte hypertrophy precedes apoptosis since inhibition of
hypertrophy decreased podocyte apoptosis, whereas prevention of apoptosis had no effect on
podocyte hypertrophy.
2.3.3.2.3. Podocyte loss
Podocyte loss by apoptosis, detachment or both, combined with their inability to proliferate, are key
components of progressive glomerulosclerosis. Podocyte loss has been reported in patients with T1D
(Steffes et al., 2001) and T2D with or without DN (Meyer et al., 1999;Nakamura et al., 2000;Verzola
et al., 2007). In addition, Verzola et al. reported glomerular apoptosis in the kidneys of patients with
DN (Verzola et al., 2007). In Pima Indians with T2D, the decreased number of podocytes per
glomerulus has been shown to be the strongest predictor of the progression of the renal disease, with
fewer cells predicting more rapid progression (Meyer et al., 1999). Podocytes can also be detected in
the urine in patients with DN and in DN animal models, and podocyte number in urine correlates with
the severity of the disease (Nakamura et al., 2000;Petermann et al., 2004).
2.3.3.3. Insulin signaling and insulin resistance in podocytes
Podocytes are insulin-responsive cells (Coward et al., 2005). Binding of insulin to its receptor on the
cell surface leads to a cascade of signaling events that lead to glucose uptake into podocytes (Figure
5). Insulin signaling in podocytes is mediated via PI3K and MAPK pathways (Welsh et al., 2010).
Kanai et al. (1993) demonstrated that insulin-dependent glucose uptake is mediated mainly through
PI3K pathway activation, since inhibition of PI3K decreased the translocation of glucose transporter
GLUT4  (Kanai  et  al.,  1993).  In  addition  to  PI3K,  the  cGMP-dependent  protein  kinase  G  (PKG)
pathway appears to stimulate glucose uptake in podocytes (Piwkowska et al., 2014). MAPK pathway,
an alternative insulin signaling pathway, does not mediate metabolic activities of insulin, but is
involved in proliferation and production of cytokines, including vasoconstrictor endothelin 1 (ET-1)
(Formoso et al., 2006;Lazar et al., 1995;Tian et al., 2000). Hale et al. (2013) showed that the signaling
of insulin-like growth factor II (IGF-II) in podocytes is mediated through the insulin-like growth
factor receptor I via PI3K and MAPK pathways (Hale et al., 2013). In the same study, a decrease in
IGF signaling resulted in podocyte death in vitro and in glomerular disease in vivo (Hale et al., 2013).
In addition, mice with deletion of the insulin receptor specifically in podocytes, developed significant
albuminuria pointing out the importance of insulin signaling in podocytes (Welsh et al., 2010).
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The connection between insulin resistance and microalbuminuria has been shown in both diabetic
(Parvanova et al., 2006;Yip et al., 1993) and non-diabetic (Palaniappan et al., 2003) individuals
suggesting that insulin resistance may induce podocyte injury. Insulin resistance in podocytes was
first shown in db/db mice at early stage of T2D, as podocytes from these mice were unable to
phosphorylate Akt in response to insulin (Tejada et al., 2008). In addition, Mima et al. (2011)
identified glomeruli as the site of insulin resistance, as streptozotocin rats with T1D and Zucker rats
with T2D showed loss of insulin signaling via P13K in glomerulus (Mima et al., 2011).
Figure 5. Schematic illustration of PI3K and MAPK insulin signaling pathways in podocytes. These
pathways are differentially regulated. SHIP2 downregulates the PI3K insulin signaling pathway by
hydrolyzing PIP3. IR: insulin receptor; IRS: insulin receptor substrate;  PI3K: phosphoinositide 3-
kinase; PDK1: 3-phosphoinositide dependent kinase; SHIP2: SH2-domain-containing inositol
polyphosphate 5-phosphate 2; PI(4,5)P2: phosphoinositol(4,5)biphosphate; PI(3,4,5)P3:
phosphoinositol(3,4,5)trisphosphate; (PI(3,4,)P2: phosphoinositol(3,4)biphosphate; MAPK:
mitogen-activated protein kinase; GLUT4: glucose transporter 4.
2.3.4. Animal models of albuminuria and diabetic kidney disease
Animal models of albuminuria and diabetic kidney disease are needed to understand the pathogenic
mechanisms of diseases such as T2D and DN, and to develop possible treatment strategies. There are
multiple murine models of diabetes, however, animal disease models do not completely resemble
human diseases. For example, most murine DN models develop only mild renal abnormalities when
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compared to human DN. However, murine models remain popular compared to other animal models
due to lower costs, large number in variety of models, the known genome and easier maintenance
(Hamamdzic and Wilensky, 2013;King, 2012).
2.3.4.1. db/db mouse
The db/db mouse was identified initially in 1966 when Hummel, Dickie and Coleman found a
recessive mutation in an inbred mouse strain causing diabetes (Hummel et al., 1966). Later the
diabetes (db) mutation was found to encode the leptin receptor (Chen et al., 1996). The db/db mouse
is a well characterized and widely used model of T2D (Sharma et al., 2003). The db/db mice are
obese, insulin resistant and hyperphagic and the degree of hyperglycemia depends on the background
strain (Hummel et al., 1972). The C57BLKS/J strain with diabetes is usually used (Hummel et al.,
1972). Key common features of the db/db mice with the human condition are albuminuria, renal
hypertrophy, GBM thickening, and mesangial expansion (Sharma et al., 2003).
2.3.4.2. Zucker rat
Obese Zucker rats (fa/fa rats) have a mutation in the leptin receptor gene (Chua et al., 1996) similar
to the db/db mouse model. Leptin receptor mutations were also identified in corpulent and fatty
Zucker rats, two considerably obese rodent models (Phillips et al., 1996;Wu-Peng et al., 1997). The
Zucker rat  is  used as a model for T2D and shows similarities to early human DN (Coimbra et  al.,
2000), including insulin resistance, obesity, hypertension and hyperlipidemia. Renal abnormalities,
including albuminuria and glomerular lesions, develop relatively late (Coimbra et al., 2000).
2.3.4.3. LPS-induced proteinuria in mice
Lipopolysaccharides (LPS) are lipid-soluble outer membrane components of the Gram-negative
bacteria. LPS injection model is widely used for sepsis research. The systemic inflammation, induced
by LPS administration mimics many of the initial clinical features of sepsis, including increases in
proinflammatory cytokines without bacteremia (Michie et al., 1988;Remick et al., 2000;Wichterman
et al., 1980). LPS also induces renal injury, including increased blood urea nitrogen (BUN), decreased
GFR, and increased renal neutrophil infiltration (Cunningham et al., 2004;Knotek et al., 2001;Tiwari
et al., 2005). High LPS doses induce systemic hypotension and decrease glomerular perfusion,
whereas low LPS doses decrease glomerular perfusion without causing systemic hypotension (Wang
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et al., 2002;Wang et al., 2003). Cani et al. (2007) reported that long-term treatment of mice with LPS
causes increased inflammation and diabetes and LPS has also been shown to induce albuminuria in
mice (Cani et al., 2007;Cunningham et al., 2000;Reiser et al., 2004). Therefore, LPS-induced
albuminuria in mice has been used as a model to study human proteinuric kidney disease (Faul et al.,
2008;Wei et al., 2008).
2.4. Podocyte apoptosis
Although the exact mechanisms causing podocyte loss in DN are not known, both apoptosis, also
known as the programmed cell death, and detachment are involved (Wolf et al., 2005). Petermann et
al. (2004) demonstrated that viable podocytes can be recovered from urine in rodent models, and
cultured ex vivo, indicating that podocytes may detach without undergoing apoptosis (Petermann et
al., 2004). However, there are studies that show podocyte apoptosis as a mechanism of podocyte loss
in DN (Susztak et al., 2006;Verzola et al., 2007). Podocyte apoptosis increased sharply with the onset
of hyperglycemia and correlated with the onset of albuminuria and preceded detectable loss of
podocytes  in  Akita  mice  with  T1D  and  db/db  mice  with  obesity  and  T2D  (Susztak  et  al.,  2006).
Furthermore, increased extracellular glucose concentration stimulated the generation of ROS in
cultured podocytes and induced apoptosis (Susztak et al., 2006). Podocyte loss by apoptosis has also
been documented as an early factor in patients with T2D (Verzola et al., 2007).
2.4.1. Anti- and proapoptotic pathways
Cell survival requires the inhibition of apoptosis, which is performed by inhibiting the expression of
pro-apoptotic factors and promoting the expression of anti-apoptotic factors.
2.4.1.1. The extrinsic and intrinsic pathways
The extrinsic pathway leading to apoptosis involves transmembrane death receptors that are members
of the tumor necrosis factor (TNF) receptor gene superfamily that consists of more than 20 proteins
with a wide range of biological functions (Ashkenazi, 2002;Locksley et al., 2001;Walczak and
Krammer, 2000). Members of this receptor family bind to extrinsic ligands and transduce intracellular
signals that eventually leads to destruction of the cell (Bazzoni and Beutler, 1996; reviewed in
Elmore, 2007).
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The intrinsic pathway for apoptosis involves non-receptor–mediated intracellular signals, enhancing
activities in the mitochondria that trigger apoptosis (Elmore, 2007). Stimuli for the intrinsic pathway
include the absence of certain growth factors, hormones and cytokines, viral infections or damage to
the cell by toxins, free radicals, or radiation. These stimuli cause changes in the inner mitochondrial
membrane that result in the loss of mitochondrial transmembrane potential, causing the release of
pro-apoptotic proteins into the cytosol and triggering apoptosis (Ashkenazi et al., 2008; reviewed in
Elmore, 2007).
In the intrinsic pathway, caspases that mediate the destruction of the cell through many pathways, are
activated by pro-apoptotic proteins. These pro-apoptotic proteins also translocate into the nucleus and
induce DNA fragmentation, known hallmark of apoptosis (Elmore,  2007).  Members of the BCL-2
family of proteins, that may be pro- or anti-apoptotic and the tumor suppressor protein p53 regulate
the pro-apoptotic events in the mitochondria (Elmore, 2007).
Both, the extrinsic and the intrinsic pathways are involved in apoptosis in podocytes. For example,
Eichler et al., (2006) showed toxic metals to induce podocyte apoptosis via the extrinsic pathway
(Eichler et al., 2006) and Mallipattu et al. (2015) suggested regulation of Krüppel-like factor 6
(KLF6), a transcriptional factor, as a potential mechanism of the intrinsic apoptotic pathway in
podocyte apoptosis (Mallipattu et al., 2015). Susztak et al. (2006) demonstrated that high glucose
stimulates ROS through NADPH oxidase and mitochondrial pathways leading to the activation of
proapoptotic p38 mitogen-activated protein kinase and caspase-3 and to apoptosis in cultured
podocytes (Susztak et al., 2006).
2.4.1.2. Caspase cascade
Caspases are a family of cysteine proteases involved in apoptosis. Caspases are synthesized in the
cell as procaspases and they are activated by cleavage with other caspases that then cleave, and
thereby activate, other procaspases, resulting in an amplifying proteolytic cascade. Activated caspases
then cleave target proteins at specific aspartate residues (Alnemri et al., 1996;Nicholson et al., 1995).
Yuan et al., (1993) were the first to find that caspases have a role in apoptosis when a cell death-
related gene, ced-3, which is essential for apoptosis in Caenorhabditis elegans, was  found  to  be
homologous  to  the  mammalian  caspases  (Yuan  et  al.,  1993).  Now  it  is  known  that  caspases  are
essential effector molecules involved in apoptosis in eukaryotic cells (Nicholson and Thornberry,
1997;Salvesen and Dixit, 1997;Thornberry and Lazebnik, 1998).
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Caspases which are activated via recruitment to signaling complexes are known as the initiator
caspases, since they provide a link between cell signaling and apoptosis. Caspase-2, -8, -9 and -10
are the main initiator caspases in mammals. Since most of the cellular targets are cleaved by
downstream caspases, these caspases are also known as the effector caspases. The main effector
caspases are caspases-3, -6 and -7 in mammals. High glucose has been shown to induce podocyte
apoptosis by increased protein expression of cleaved caspase-3 in vitro (Liu et al., 2012). Similarly,
Lee et al. (2015) demonstrated upregulation of cleaved caspase-3 in addition to increase in Bax/Bcl-
2 ratios in vitro in high glucose-stimulated podocytes and in vivo in glomeruli of streptozotocin
induced diabetic rats (Lee et al., 2015). Also, puromycin aminonucleoside (PA) induced apoptosis by
increasing the activation of caspase-3 in podocytes (Li et al., 2014).
2.4.1.3. PI3K/Akt pathway
The phosphoinositide 3-kinases (PI3K) are linked to multiple cellular functions via the activation of
Akt, an important player in survival signaling (Figure 6). These functions include proliferation,
differentiation, cell growth, metabolism and survival (Katso et al., 2001;Saudemont and Colucci,
2009). PI3K activation has shown to play a role also in diabetic complications. Ha (2010) showed
that both high glucose and advanced glycosylation end products caused podocyte hyperpermeability
via PI3K/Akt signaling pathway (Ha, 2010). Bridgewater et al., (2005) demonstrated that human
podocytes were protected from etoposide-induced apoptosis by insulin-like growth factors through
the PI3K pathway (Bridgewater et al., 2005). Similarly, aldosterone was shown to induce apoptosis
in rat podocytes through inhibition of PI3K/Akt pathway (Chen et al., 2009). Tejada et al. (2008)
showed that Akt phosphorylation was downregulated in both glomeruli and podocytes of db/db mice
compared to db/+ mice and podocytes (Tejada et al., 2008). Also, Akt activation has been recognized
as a key survival factor for podocytes exposed to oxidized low-density lipoproteins (Bussolati et al.,
2005). As well, darbapoietin was shown to protect podocytes from ultraviolet-C irradiation induced
apoptosis via Akt activation (Logar et al., 2007). Therefore, loss of podocytes in early stages of DN
may occur via an inability by PI3K pathway to phosphorylate Akt in response to physiological
stimuli.
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Figure 6. Schematic illustration of PI3K-dependent Akt and p38 MAPK signaling in apoptosis.
Activation of p38 MAPK induces apoptosis by caspase-3 activation and PI3K activates Akt and Akt
protects from apoptosis. Akt may also inhibits caspase-3 activity and therefore delay apoptosis. PI3K:
phosphoinositide 3-kinase; p38 MAPK: p38 mitogen-activated protein kinase.
2.4.1.4. p38 MAPK pathway
p38 mitogen-activated protein kinase (p38 MAPK), a stress-activated serine/threonine protein kinase,
belongs to the MAP kinase superfamily and it plays a major role in various cellular processes
including  apoptosis, cell growth, cell differentiation, inflammation, and responses to environmental
stresses  (Kim  et  al.,  2012;Sayama  et  al.,  2006).  It  has  been  shown  that  activation  of  p38  MAPK
induces apoptosis in human neutrophils by activating caspase-3 and that survival signaling pathway
via Akt activation inhibits caspase-3 activation and therefore delays apoptosis (Khreiss et al., 2002)
(Figure 6). Verzola et al. (2007) demonstrated that p38 MAPK expression was increased in glomeruli
and tubules of patients with type 2 DN, but this did not correlate with apoptosis (Verzola et al., 2007).
Still, p38 MAPK activation has been suggested to be involved in apoptotic cell loss in diabetes. For
instance, Adhikary et al. (2004) demonstrated that p38 MAPK signaling is increased in human and
experimental DN (Adhikary et al., 2004). Also, Chen et al. (2009) demonstrated that aldosterone
induced apoptosis in rat podocytes through activation of p38 MAPK pathway in addition to inhibition
of PI3K/Akt pathway (Chen et al., 2009).
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2.5. Anti- and proapoptotic factors in podocytes
Nephrin is known to interact with the PI3K and induce activation of the Akt signaling pathway (Huber
et al., 2003). Additionally, Li et al. (2015) showed that nephrin-knockdown mice developed more
podocyte apoptosis and depletion and reduced Akt phosphorylation after being subjected to
doxorubicin (Li et al., 2015). In addition to nephrin, CD2AP also stimulates PI3K-dependent Akt
signaling pathway that is one of the main antiapoptotic cell survival pathways (Huber et al., 2003).
TGF-ß1-induced activation of Akt was shown to require CD2AP, since the lack of CD2AP enhanced
the activation of the proapoptotic p38 MAPK pathway by TGF-ß1 (Schiffer et al., 2004). Nephrin
and CD2AP also form a complex with dendrin that in response to podocyte injury translocates to the
nucleus and enhances TGF-ß1-induced apoptosis (Asanuma et al., 2007). Peng et al. (2015) recently
showed that expression of toll-like receptor 2 (TLR2) was increased in podocytes in mice with acute
kidney injury (AKI) suggesting that TLR2 induces apoptosis in podocytes in AKI (Peng et al., 2015).
2.6. Induction of podocyte apoptosis
Several factors have been shown to induce podocyte apoptosis. For example, high glucose, ROS,
angiotensin II, PA and LPS/endotoxins (Chen et al., 2009;Jia et al., 2008;Li et al., 2014;Li et al.,
2013;Srivastava et al., 2013;Susztak et al., 2006), have been shown to induce podocyte injury.
2.6.1. High glucose
High glucose was shown increase ROS production through NADPH oxidase and mitochondrial
pathways, which led to activation of p38 MAPK and caspase-3 and induction of podocyte apoptosis
in vitro (Susztak, et al., 2006). Susztak, et al. (2006) also demonstrated increased podocyte apoptosis
in Akita mice with T1D and db/db mice with T2D with onset of hyperglycemia (Susztak et al., 2006).
Liu et al, (2013) showed that high glucose induces apoptosis in podocytes by upregulation of TRPC6
via ROS induction (Liu et al., 2013). In addition, high glucose has been shown to induce upregulation
of TRPC6 leading to activation of the canonical Wnt signaling pathway and apoptosis in podocytes
(Li et al., 2013).
29
2.6.2. Inflammation/Lipopolysaccharides
Sepsis, a lethal syndrome that develops in response to infection, is one of the main causes of acute
kidney injury in hospitalized patients (Schrier and Wang, 2004). Lipopolysaccharides (LPS), fat-
soluble outer membrane components of Gram-negative bacteria, have been shown to play a critical
role in sepsis by activation of Toll-like receptor 4 (TLR4) inflammatory signaling pathways (Akira
et al., 2006;Armstrong et al., 2004;Cohen, 2002;Poltorak et al., 1998). In mice, LPS-treatment
induces albuminuria (Cunningham et al., 2000;Reiser et al., 2004), and long-term LPS-treatment
causes increased inflammation and diabetes (Cani et al., 2007). LPS has also been shown to induce
apoptosis in kidney cells and in podocytes (Cunningham et al., 2002;Guo et al., 2004;Sun et al.,
2009b).
2.6.3. Puromycin aminonucleoside
PA, a classic podocyte toxin has been shown to induce podocyte apoptosis both in vitro and in vivo.
Injection of PA to rats induces massive proteinuria and mimics the lesions of minimal change disease
or focal segmental glomerular sclerosis (Hagiwara et al., 2006). PA induces podocyte injury, leading
to foot process effacement, decreased expression of slit diaphragm proteins and actin cytoskeleton
disorganization (Guan et al., 2004;Smoyer et al., 1997). PA induced podocyte injury has been shown
by in vivo studies to be mediated via overproduction of ROS (Beaman et al., 1987;Diamond et al.,
1986;Gwinner et al., 1997;Nakamura et al., 1998;Ricardo et al., 1994;Thakur et al., 1988). Xiao et al
(2008) showed that vitamin D was able to reduce PA-induced podocyte apoptosis in rats (Xiao et al.,
2009). Also antithrombin (Yamashita et al., 2008), triptolide (Zheng et al., 2008), upregulation of
nestin (Wen, et al., 2011), dexamethasone (Wada et al., 2005) and downregulation of TRPC6 (Sun et
al., 2009a) have been shown to protect podocytes against PA-induced injury and apoptosis.
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3. AIMS OF THE STUDY
The mechanisms leading to the development of DN remain unclear, but podocyte injury is involved.
Podocyte detachment and apoptosis are the two main factors causing podocyte loss in DN. Even
though podocyte apoptosis is an early feature of DN and predicts its progression, the mechanisms and
molecular pathways involved are poorly characterized. This study aimed to investigate the functions
of SHIP2, PDK1 and CDK2 in the Akt cell survival pathway and in podocyte apoptosis.
The specific aims of this thesis were:
I. To study the role of SHIP2, an interaction partner of CD2AP in antiapoptotic Akt signaling
pathway and in podocyte apoptosis.
II. To investigate the role of PDK1 and the molecular pathways involved in LPS-induced
podocyte injury.
III. To characterize the role of CDK2 in different podocyte injury models and to investigate
the signaling pathways involved.
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4. MATERIALS AND METHODS
4.1. Experimental animals
4.1.1. Sprague–Dawley rats and FVB mice (Studies I-III)
The  kidneys  of  Sprague–Dawley  rats  and  FVB  mice  were  used  to  study  the  expression  and
localization of SHIP2 and PDK1. Wild type mouse kidneys were used to study CDK2 expression and
localization. The kidneys were perfused with PBS for 30 minutes at RT before collecting the kidneys.
4.1.2. db/db mice (Study I)
Male db/db mice and heterozygous db/+ controls in C57BLKS background (BKS.Cg-
m+/+Leprdb/BomTac, Taconic Europe, Ry, Denmark) were used to investigate SHIP2 expression in
diabetic mouse glomeruli. Blood glucose values and creatinine and urinary albumin measurements of
the db/db mice are described in Study I. Animal care followed the guidelines of NIH and Finnish
laws.
4.1.3. Zucker rats (Studies I-III)
Obese (fa/fa) and lean (fa/+) Zucker rats (Crl:ZUC-Leprfa) were purchased  from Charles River
Laboratories (Sulzfeld, Germany). Blood glucose, creatinine and urinary albumin measurements of
the Zucker rats are described in Study I. Animal work was approved by the National Animal
Experiment Board.
4.1.4. LPS-induced albuminuric mouse model (Studies II and III)
Female BALB-C mice (BALB/cAnNCrl) were purchased from Scanbur (KarlslundeDenmark). Mice
were treated with LPS (Sigma-Aldrich, St. Louis, MO) and TLR4 inhibitor 2-(3-Phenyl-4,5-dihydro-
1,2-oxazol-5-yl)acetic acid (GIT27) (Tocris Bioscience, Bristol, UK), LPS and PBS or PBS only as
described in Study II. Urinary albumin and creatinine analyses were carried out at the Biochemical
Analysis Core for Experimental Research (http://www.biomed.helsinki.fi/research/services/bacer/) at
the Institute of Biomedicine, University of Helsinki with ADVIA 1650 Chemistry System (Siemens
AG Healthcare, Erlangen, Germany) according to manufacturer's instructions. Mice were maintained
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according to the principles of laboratory animal care, and the experiments were approved by the
National Animal Experiment Board.
4.2. Human study subjects
4.2.1. Human kidney samples (Study II)
Kidney  samples  of  renal  cancer  patients  with  or  without  T2D  were  obtained  from  surgical
nephrectomies performed at Helsinki and Uusimaa Hospital district, and were from the nonmalignant
part of the kidney. Albuminuria was determined from the medical records. The use of human material
was approved by the local Ethics Committee.
4.2.2. Human sera (Studies II and III)
Serum samples were obtained from patients with T1D that were recruited and examined by the
Finnish Diabetic Nephropathy Study (FinnDiane; www.finndiane.fi). Serum LPS activities were
determined in 39 T1D patients with normal urinary albumin excretion (AER <30 mg/24 h) as
described in (Nymark et al., 2009). Sera with the highest (n=6) and lowest (n=6) LPS-activities were
selected for the treatment of podocytes (Study I, Supplementary Table S1). Differentiated human
podocytes were treated with 10% human sera for 72 h. GIT27 (Tocris Bioscience) (10 µg/ml) was
added  to  the  media  2  h  before  addition  of  human sera  with  high  LPS activity.  The  use  of  human
material was approved by the local Ethics Committee.
4.3.  Cell culture (Studies I-III)
Conditionally immortalized human podocytes were maintained as previously decribed in (Saleem et
al., 2002).  Shortly, cells were maintained in RPMI media supplemented with 10% fetal bovine serum
(FBS), 1% glutamine, and insulin, transferrin and sodium selenite (ITS) at +33°C for proliferation.
To induce differentiation, podocytes were transferred to non-permissive conditions at +37°C for 14
days (Studies I-III). HEK293FT cells (Invitrogen, Carlsbad, CA) were cultured in DMEM medium,
supplemented with 10% FBS, ultraglutamine, penicillin and streptomycin. Media, FBS and ITS were
obtained from Sigma-Aldrich and ultraglutamine from Lonza (Basel, Switzerland) (Studies I-III).
HIRc cells (rat fibroblasts overexpressing human insulin receptor) (McClain et al., 1987) were
maintained in DMEM medium, supplemented with 10% FBS, ultraglutamine, penicillin and
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streptomycin (Study I). All cell culture reagents were from Sigma-Aldrich (St. Louis, MO) except
ultraglutamine from Lonza.
4.4. Antibodies (Studies I-III)
The primary and secondary antibodies used in Studies I-III are presented in Table 1 and Table 2.
Table 1. Primary antibodies used in Studies I-III.
Primary antibody Description Reference / supplier Study
SHIP2 I-20 goat polyclonal
Santa-Cruz Biotechnology  (Dallas, Texas,
USA)
I
CD2AP 1774 rabbit polyclonal Lehtonen et al., 2000 I
CD2AP 1764 rabbit polyclonal Lehtonen et al., 2000 I
phosphotyrosine PT-66
mouse
monoclonal
Sigma-Aldrich I
phosphorylated Akt
(Ser473)
rabbit polyclonal
Cell Signalling Technology (Danvers, MA,
USA)
I, II, III
Pan Akt
mouse
monoclonal
R&D Systems (Minneapolis, MN, USA) I, II, III
WT1
mouse
monoclonal
Upstate (New York, USA) II
caspase-3
mouse
monoclonal
Cell Signalling Technology II
podocin rabbit polyclonal Sigma-Aldrich II
PDK1 rabbit polyclonal Cell Signalling Technology II, III
p38 MAPK rabbit polyclonal Cell Signalling Technology II, III
phosphorylated p38
MAPK
(Thr180/Tyr182)
rabbit polyclonal Cell Signalling Technology II, III
cleaved caspase-3 rabbit polyclonal Cell Signalling Technology II, III
active caspase-3 rabbit polyclonal Abcam (Cambridge, UK) II, III
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BAX rabbit polyclonal Abcam II, III
BCL-2 rabbit polyclonal Abcam II, III
CDK2
mouse
monoclonal
Santa-Cruz Biotechnology III
CDK2 rabbit polyclonal
Bethyl laboratories (Montgomery, TX,
USA)
III
CDK2 rabbit polyclonal Abcam III
nephrin
guinea pig
polyclonal
PROGEN Biotechnik (Heidelberg,
Germany)
III
actin
mouse
monoclonal
Sigma-Aldrich I, II, III
tubulin
mouse
monoclonal
Sigma-Aldrich I, II, III
Table 2. Secundary antibodies used in Studies I-III.
Secondary antibody Description Reference / supplier Study
AlexaFluor 680 goat anti-mouse Invitrogen (Carlsbad, CA) I, II, III
IRDye 800
donkey anti-
rabbit
LI-COR (Lincoln,NE) I, II, III
IRDye 800 donkey anti-goat LI-COR I, II, III
IRDye 800
donkey anti-
mouse
LI-COR I, II, III
AlexaFluor 555
donkey anti-
rabbit
Invitrogen II, III
DyLight 488
donkey anti-
mouse
Jackson Immuno Research Laboratories
Inc. (West Grove, USA)
II
AlexaFluor 555
goat anti-guinea
pig
Invitrogen III
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4.5. Protein studies and biochemical experiments
4.5.1. Yeast two-hybrid screening (Study I)
The N-terminal part of mouse CD2AP cDNA (amino acids 1–330) was amplified by PCR and
subcloned into NcoI and XhoI sites in the LexA DNA-binding domain-containing displayBAIT
vector (DisplaySystem Biotech, Vista, CA). The displayBAIT-CD2AP together with the green
fluorescent protein containing displayREPORTER vector were transformed into yeast strain EGY48
(Invitrogen). The rat glomerular yeast two-hybrid library (Takeda et al., 2001) in the displayTARGET
vector was transformed into yeast pretransformed with displayBAIT-CD2AP and
displayREPORTER vectors and plated on selective medium. Colonies expressing the green
fluorescent protein reporter were selected. Plasmid DNA of the positive clones was electroporated
into Escherichia coli KC8 (Clontech, MountainView, CA, USA) and the identity of the inserts was
analyzed by sequencing.
4.5.2. Immunoblotting (Studies I-III)
Cells were washed twice with phosphate-buffered saline (PBS) and scraped from the dish into ice-
cold 1% Nonidet P-40 (NP-40), 20 mM Hepes, pH 7.5, 150 mM NaCl with 1× CompleteTM, EDTA-
free proteinase inhibitor cocktail (Roche), 50 mM NaF and 1 mM Na3VO4 (lysis buffer) and rotated
at 4◦C for 15 min. Glomeruli and tubules were isolated from rat kidney cortices by graded sieving
and lysed by rotation in lysis buffer at 4◦C for 30 min. Detergent insoluble material was removed by
centrifugation (10,000×g for 10 min). For immunoblotting, proteins were separated by SDS-PAGE
and  transferred  to  PVDF-FL  membranes  (Millipore,  Billerica,  MA)  and  blocked  with  Odyssey
blocking buffer (LI-COR) diluted 1:1 with PBS or TBS. Membranes were incubated for 1h at room
temperature or overnight at +4°C with primary antibodies, followed by 1 h incubation with secondary
antibodies. Detection and quantification was performed with an Odyssey Infrared Imager (LI-COR).
4.5.3. Pull-down assay (Study I)
Generation of glutathione-S-transferase (GST)-tag fusion protein constructs of mouse CD2AP SH3
domains is described in (Palmen et al., 2002). The N-terminal part of mouse CD2AP (aa1–330) was
subcloned into pGEX-4T-1 vector (Amersham Biosciences, Buckinghamshire, England) to produce
GST-CD2AP-N. GST and GST-CD2AP fusion proteins were produced in Escherichia coli BL21
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(DE3) (Stratagene; LaJolla, CA) and purified on glutathione- Sepharose beads (Amersham
Biosciences). Cell and glomerular lysates were incubated with glutathione-Sepharose beads at 4◦C
for 1h, followed by incubation at 4◦C for 4h with GST-CD2AP fusion proteins or GST beads. Beads
were washed with lysis buffer, boiled in Laemmli sample buffer and proteins were separated by SDS-
PAGE for immunoblotting with anti-SHIP2 I-20 (Study I).
4.5.4. Immunoprecipitation (Study I)
HIRc cells in basal state, starved for 16 h, or starved for 16 h and stimulated with 17 nM insulin for
7 min were lysed. Lysates were incubated with protein A-Sepharose beads (Invitrogen) or TrueBlot
anti-goat Ig IP Beads (eBioscience, SanDiego, CA) at 4◦C for 1 h, followed by incubation with anti-
CD2AP 1764 (Lehtonen et al., 2000) or normal rabbit serum, or alternatively, with anti-SHIP2 I-20
or  goat  IgG  for  16–20  h  at  4  C.  Protein  complexes  were  bound  to  protein  A-Sepharose  or  goat
TrueBlot beads at 4◦C for 1 h, washed and boiled in Laemmli sample buffer for immunoblotting with
anti-SHIP2 I-20, anti-CD2AP 1764, or anti-phosphotyrosine.
4.5.5. High glucose and insulin treatments (Studies I-III)
Human podocytes were cultured at +37◦C for 14 days in RPMI medium containing 30 mM glucose,
or mannitol (osmolality control) (Studies I and II), or for 72 hours in RPMI medium containing 30
mM glucose (Study III). For insulin stimulations, differentiated podocytes or podocytes
overexpressing SHIP2 were serum and ITS starved overnight and stimulated with 200 nM insulin for
15 min (Study I).
4.5.6. Transfections and infections (Studies I-III)
For SHIP2 overexpression, proliferating human podocytes were transfected for 48 h with human
SHIP2 cDNA with HA-tag in pCGN vector (SHIP2-pCGN) (Dyson et al., 2001) or empty pCGN
using Lipofectamine 2000 (Invitrogen). Differentiated podocytes were infected using lentiviral
overexpression for SHIP2. For lentiviral overexpression, SHIP2 with HA-tag was subcloned from
SHIP2-pCGN into pSIN18.cppt.hEF1αp.WPRE vector (Gropp et al., 2003). Empty
pSIN18.cppt.hEF1αp.WPRE vector was used as a control. For virus production for SHIP2
overexpression, KSpCMVα8.9 and pHCMV packaging plasmids, together with SHIP2 or control
lentiviral vector, were transfected into HEK293FT cells (Invitrogen) with Lipofectamine 2000. Virus-
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containing media were collected 72 h later, filtrated through 0.45 µm filter, and concentrated by
ultracentrifugation. Viruses were resuspended in PBS, added to podocytes on day 10 or 11 of
differentiation and incubated at +37°C for 10 min, followed by centrifugation 1360×g at +4 °C for
30 min. Virus-containing medium was replaced with regular medium after 24 h (Study I).
In order to knock down PDK1 in differentiated human podocytes, lentiviral human pLKO1-shPDK1
vectors PDK1A (GAAGGTATATTAGGACATTTG) and PDK1B
(TATAGACTCAGAAGGTATATT) were used. Human lentiviral pLKO1-shCDK2 vectors,
CDK2A (CTCCTGGGCTGCAAATATTAT) and CDK2B (CCTCAGAATCTGCTTATTAAC)
(Biomedicum  Genomics,  University  of  Helsinki,  Finland)  were  used  to  knock  down  CDK2  in
differentiated human podocytes. An empty pLKO1 vector was used as a control for both PDK1 and
CDK2 knockdowns. For virus production, CMVDelta8.9 and phCMVg packaging plasmids, together
with  PDK1A,  PDK1B,  CDK2A,  CDK2B  or  pLKO1,  were  transfected  into  HEK293FT  cells
(Invitrogen) with Lipofectamine2000 (Invitrogen). Media was collected and podocytes infected as
described above (Studies II and III).
4.5.7. Induction of apoptosis (Studies I-III)
Apoptosis was induced by exposing differentiated podocytes to PA (50 µg/ml (Sigma-Aldrich) or
LPS (100 ng/ml Escherichia coli 0111:B4 LPS (Sigma-Aldrich)) for 48 h. The activity of 100 ng/ml
LPS in cell culture media (1.7 EU/ml) was measured as described (Nymark et al., 2009). GIT27
(Tocris Bioscience) (10 µg/ml) was added to the cells 2 h before LPS exposure.
4.5.8. Detection of apoptosis (Studies I-III)
4.5.8.1. FACS (Studies I-III)
Apoptosis was detected by fluorescence-activated cell sorting (FACS) using Annexin V-FITC
Apoptosis Kit (Pharmingen, BD, Franklin Lakes, NJ) and doublestaining with 7-Aminoactinomycin
D (7-AAD) (BD). Cells were trypsinized, combined with detached cells in media, and centrifuged.
Cell pellet was washed with cold PBS and resuspended in Annexin V Binding Buffer (BD) containing
Annexin V-FITC and 7-AAD. Cells were incubated for 15 min at room temperature in dark, washed
with cold PBS and centrifuged. Infected cells were fixed with 4% paraformaldehyde (Electron
Microscopy Sciences, Hatfield, PA). After fixation, cells were washed with PBS, centrifuged, and
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analyzed using FACSAria (BD). Cells positive for Annexin V-FITC and negative for 7-AAD were
deemed apoptotic. A total 1 x 104 cells were detected by FACS in each sample.
4.5.8.2.  In-Cell Western (Studies I-III)
Apoptosis was also detected by In-Cell Western using black 96-well plates (PerkinElmer, Waltham,
MA, USA). For In-Cell Western, podocytes were fixed with 4% paraformaldehyde (Electron
Microscopy Sciences, Hatfield, PA, USA) in PBS and permeabilized with 0.1% Triton X-100 in PBS.
Cells were incubated with primary antibody at room temperature for one hour, followed by secondary
antibody and 1 µM DRAQ5TM (Thermo Fisher Scientific, Waltham, MA, USA) incubation at room
temperature for one hour. Detection and quantification was performed with an Odyssey Infrared
Imager (LI-COR). Apoptosis was also detected by immunoblotting as described in 4.5.2.
4.6. Immunofluorescence microscopy (Studies I-III)
Differentiated podocytes were fixed with 2% or 4% paraformaldehyde (Electron Microscopy
Sciences) in PBS and permeabilized with 0.1% Triton X-100 in PBS. Rat kidney cryosections were
fixed with acetone. Samples were blocked with CAS-block (Invitrogen), incubated with primary
antibodies  for one hour at room temperature (cells) or overnight at +4°C (tissue sections) in
ChemMate (Dako Cytomation, Glostrup, Denmark), washed with PBS and incubated with secondary
antibody  and  Hoechst  staining  DNA  (Fluka,  Sigma-Aldrich)  for  1  h  in  ChemMate  (Dako
Cytomation). Samples were mounted in Mowiol and examined with Zeiss Axiophot 2 microscope
(Carl Zeiss Microscopy GmbH, Jena, Germany) or Leica SP2 confocal microscope (Leica
Microsystems CMS GmbH, Mannheim, Germany).
For CDK2 stainings, perfused mouse kidney samples were fixed with formaldehyde and embedded
in paraffin. Deparaffinized sections were blocked with CAS-block (Invitrogen), incubated with
primary antibodies overnight at +4°C in ChemMate (Dako Cytomation), washed with PBS and
incubated with secondary antibodies. Samples were mounted in Vectashield with DAPI (Vector
Laboratories,  Burlingame,  CA)  and  examined  with  Leica  TCS  CARS  SP8  confocal  microscope
(Leica Microsystems CMS GmbH, Mannheim, Germany) (Study III).
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4.7. Immunohistochemistry (Studies I-III)
4.7.1. Immunohistochemistry of mouse kidney samples (Studies I-III)
Mouse kidney samples were fixed with formaldehyde, dehydrated and embedded in paraffin.
Immunoperoxidase staining was performed with a Vecta Stain Elite ABC kit (Vector Laboratories,
Burlingame, CA). Sections were deparaffinized, antigen retrieval was done by boiling for 15 min in
a microwave oven in 10 mM citric acid, pH 6.0 (Studies II-III), and endogenous peroxidase was
inactivated by incubation in 0.5% hydrogen peroxide in methanol for 30 min. Sections were blocked
with CAS-block (Zymed, South San Francisco, CA or Invitrogen) and incubated with primary
antibodies diluted in ChemMate TM (Dako, Glostrup, Denmark) and with biotinylated secondary
antibodies followed by detection with VectaStain Elite ABC kit and AEC (Dako Cytomation). Slides
were counterstained with hematoxylin, mounted with Shandon Immu-Mount (ThermoScientific,
Waltham, MA) and photographed using Nikon Eclipse 800 microscope using the same microscope
settings throughout the analysis. The staining intensity of SHIP2, PDK1 and CDK2 in mouse kidneys
was visually graded by two independent researchers blinded from the treatment group.
4.7.2. Immunohistochemistry of human kidney samples (Study II)
Human kidney samples were fixed and stained as described above. Sections were counterstained with
hematoxylin and photographed using Nikon Eclipse 800 microscope using the same microscope
settings throughout the analysis.
4.8. Electron microscopy (Studies II and III)
Mouse kidney samples were fixed at room temperature for 2 h in 1.5% glutaraldehyde, 3%
paraformaldehyde, 5% sucrose in 0.1 M cacodylate buffer, pH 7.4, postfixed in 1% osmium tetroxide
(OsO4)  in  the  same  buffer  for  1  h,  stained  en-bloc  in  1%  uranyl  acetate  in  10%  ethanol  for  1  h,
dehydrated in ethanol and embedded in Epon. Samples were stained with uranyl acetate and lead
citrate and examined with JEM-1400 Transmission Electron Microscope (Jeol, Tokyo, Japan)
equipped with Olympus-SIS Morada digital camera (Olympus Soft Imaging Solutions GmbH,
Münster, Germany). Foot process width was determined as described (van den Berg et al., 2004).
Briefly,  the number of foot processes per capillary loop was counted, divided by the length of the
GBM, and multiplied by π/4. Calculations were performed on 3-4 animals per group, 3 glomeruli per
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animal and the foot process width was expressed as averages of measurements of three capillary loops
per glomerulus.
4.9. Statistical analyses (Studies I-III)
All variables were presented as mean ± STDEV. In all experiments, the differences between groups
were determined with the Student's t-test (GraphPadPrism6, GraphPad Software Inc, La Jolla, CA,
USA). For all statistics, p-values of less than 0.05 were considered statistically significant.
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5. RESULTS
5.1. Study I: Lipid phosphatase SHIP2 downregulates insulin signaling in podocytes
5.1.1. CD2AP interacts with SHIP2 in glomeruli
CD2AP is critical to the structural and functional integrity of the glomerular filtration barrier as mice
lacking CD2AP develop nephrotic syndrome with heavy proteinuria and effacement of podocyte foot
processes (Shih et al., 1999). A yeast two-hybrid screening of a rat glomerular library was performed
to  study  the  role  of  CD2AP in  podocyte  injury.  SHIP2,  a  lipid  phosphatase  that  hydrolyzes  the  5-
position phosphate of phosphoinositol(3,4,5)trisphosphate (PI(3,4,5,) P3) to generate
phosphoinositol(3,4)bisphosphate (PI(3,4) P2),  and thus negatively regulates the PI3K pathway
mediating various metabolic effects of insulin (Dyson et al., 2005), was found to bind to CD2AP. The
function of SHIP2 in the kidney has not been studied, although SHIP2 has previously been shown to
be widely expressed in different tissues (Schurmans et al., 1999). Immunoblotting of isolated rat
glomeruli and tubuli was used to confirm the expression of SHIP2 in glomeruli and tubuli (Study I,
Figure 1A). Immunoperoxidase staining of mouse kidney sections indicated that in the glomeruli
SHIP2 localizes in podocytes (Study I, Figure 1B-D).
The yeast two-hybrid screening revealed that the C terminus of SHIP2 binds to CD2AP. Based on
the sequence analysis, the COOH-terminal region contains a proline-rich domain that mediates the
interaction of SHIP2 with the NH2-terminus of CD2AP harboring the SH3 domains. A pull-down
assay on mouse podocyte cell  lysates with GST-CD2AP 1.,  2.  and 3.  SH3 domains and the GST-
CD2AP-NH2-terminus was performed in order to identify, which one of the three SH3-domains of
CD2AP mediates the interaction between SHIP2 and CD2AP. The pull-down assay confirmed the
interaction between SHIP2 and CD2AP in glomeruli and suggested that the binding is primarily
mediated by the 3. SH3-domain of CD2AP (Study I, Figure 2A and B).
A co-immunoprecipitation assay in rat fibroblasts expressing the human insulin receptor (HIRc)
showed that CD2AP antibodies co-immunoprecipitated SHIP2 confirming the physiological
interaction between SHIP2 and CD2AP (Study I, Figure 2C). The interaction was not dependent of
insulin stimulation, since there was no difference in the interaction between basal state, starved and
insulin stimulated cells. There were two separate forms of SHIP2 and only the one of lower molecular
weight was precipitated by CD2AP. Immunoprecipitation with anti-SHIP2 IgG followed by Western
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blotting with anti-phosphotyrosine antibodies revealed the upper band to be phosphorylated SHIP2
(Study  I,  Figure  2D).  Interestingly,  CD2AP  seemed  to  bind  only  to  SHIP2  in  its  non-tyrosine
phosphorylated form.
5.1.2. SHIP2 expression and localization after insulin and high glucose treatment in cultured
podocytes
To study the effect of high glucose treatment on SHIP2 expression, human podocytes were cultured
in cell culture medium containing high glucose for the time of their differentiation (two weeks) or
mannitol (osmotic control). SHIP2 was expressed at equal levels in both conditions, and also the Akt
phosphorylation response to insulin was similar. This confirmed that SHIP2 expression level in
cultured podocytes is not controlled by high glucose concentration. In basal and starved state in
differentiated podocytes, SHIP2 localizes mainly in the cytoplasm, but after insulin stimulation, it was
partly translocated to plasma membrane (Study I, Figure 3A-D). The cytoplasmic localization of
CD2AP was not changed after insulin stimulation (Study I, Figure 3E and F).
5.1.3. Overexpression of SHIP2 downregulates insulin signaling and induces apoptosis in
podocytes
Since activation of the PI3K pathway by insulin leads to phosphorylation of Akt protein kinase, the
role  of  SHIP2  in  the  PI3K  pathway  was  studied  by  measuring  the  phosphorylation  of  Akt  in
differentiated human podocytes overexpressing SHIP2. There was no difference in Akt
phosphorylation in unstimulated cells when SHIP2 overexpressing cells were compared with control
cells transfected with an empty vector (Study I, Figure 4A). Akt phosphorylation level remained
15.5% lower in SHIP2 overexpressing cells when podocytes were stimulated with insulin, (Study I,
Figure  4B).  These  results  were  confirmed  with  an  ELISA-based  Akt  activity  assay.  There  was  no
difference in Akt activity after insulin stimulation in SHIP2 overexpressing cells (Study I, Figure 5A),
whereas in control cells Akt activity was increased by 32% (Study I, Figure 5B). Akt activation results
indicate that SHIP2 downregulates the insulin signaling pathway in podocytes.
Since PI3K-dependent Akt signaling pathway has also a protective role in regulating cell survival in
podocytes, we next studied the effect of SHIP2 overexpression on apoptosis. SHIP2 overexpression
increased apoptosis in differentiated human podocytes to 8.6% when compared to control podocytes
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infected with empty vector showing an apoptosis rate of 4.5%, indicating that SHIP2 has a role in
regulating podocyte apoptosis (Figure 7 and Study I, Figure 6).
Figure 7. SHIP2 overexpression increases apoptosis in cultured podocytes. A: Flow cytometry of
podocytes stained with Annexin V shows that SHIP2 overexpression increases podocyte apoptosis
compared to podocytes infected with empty vector (EV). The experiments were performed three
times with three replicates in each experiment. The bars (A) show the mean expression in arbitrary
units (error bars STDEV). **p < 0.01, Student's t-test.
5.1.4. SHIP2 is upregulated in glomeruli of diabetic rats and mice
Zucker rats and db/db mice that are both insulin resistant and slightly diabetic due to a mutation in the
leptin receptor gene (Chua et al., 1996), were used to study the expression of SHIP2 in vivo. In Zucker
rats, kidneys were analyzed from three lean and three obese rats at 12 weeks of age and from six lean
and six obese rats at 40 weeks of age. 40 weeks old obese rats had developed proteinuria, as the urine
albumin/creatinine ratio was higher in obese rats than in controls. These rats had also slightly higher
weights and blood glucose levels than the controls, but these differences were not statistically
significant. Both age groups showed upregulation of SHIP2 expression in obese (fa/fa) rats when
compared to lean controls (fa/+) (Study I, Figure 7).
db/db mice also had notable albuminuria at the age of 8 weeks and were highly hyperglycemic and
clearly obese compared to heterozygous db/+ controls (Study I, Table 1). SHIP2 expression level in
immunoperoxidase stained kidney sections was analyzed by two independent researchers blinded
from the genotypes in eight glomeruli from each sample. Although there was a trend of higher
expression of SHIP2 in db/db mice when compared to db/+ controls, it was not significantly increased
(Study I, Figure 8).
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5.1.5. SHIP2 is upregulated in PA-induced podocyte injury in vitro
PA is a toxin that induces experimental minimal change nephrosis in rats (Marshall et al., 2006). PA
is also known to induce podocyte injury and apoptosis both in vitro and in vivo (Srivastava et al.,
2013;Sun et al., 2009a;Xiao et al., 2009). PA-treatment of differentiated human podocytes increased
the expression level of SHIP2 and induced apoptosis 48 hours after exposure (Figure 8).
Figure 8. SHIP2 expression is upregulated in human podocytes treated with PA. A: Quantification
of In-Cell  Western of SHIP2 in podocytes treated with PA shows that the expression of SHIP2 is
higher after PA- treatment.  DRAQ5TM was used for normalization.The experiment was performed
three times with 24 replicates per group. The bars (A) show the mean expression in arbitrary units
(error bars STDEV). ***p < 0.001, Student's t-test.
5.2. Study II: Podocyte apoptosis is prevented by blocking the Toll-like receptor
pathway
5.2.1. PDK1 expression is reduced and apoptosis increased in cultured human podocytes
treated with sera with high LPS activity from T1D patients
PDK1 is a serine/threonine kinase known to play an essential role in Akt signaling in various cell
types, but its function in podocytes hasn’t been studied before. To study the role of PDK1 in
podocytes, we first confirmed that it is expressed in glomeruli and tubuli by immunoblotting of
isolated rat glomerular and tubular fractions (Study II, Figure 1A). Expression of PDK1 in the nuclei
of podocytes was confirmed by double labeling of rat kidney sections with PDK1 and Wilms tumor
1 (WT1) antibodies (Study II, Figure 1D-F). In addition, double labeling of normal rat kidney sections
with PDK1 and nephrin antibodies confirmed that PDK1 is expressed in the cytoplasm of podocytes
(Figure 7). PDK1 is also detected in other glomerular cells (Figure 9).
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Figure 9. PDK1 is expressed in glomerular podocytes. (A-C) Rat kidney sections stained for PDK1
(A)  and  WT1  (B) show that PDK1 localizes in nuclei (arrows) in podocytes as visualized in the
merged image (C). (D-F) Double labeling of PDK1 (D) and nephrin (E) indicates that PDK1 is also
expressed in the podocyte cytoplasm (arrows) as visualized in the merged image (F).  (A-F) Rat
kidney cryosections were fixed with acetone, labeled with anti-PDK1, anti-WT1 and anti-nephrin
IgGs, and examined by confocal microscopy. Scale bars: (A-C) 50 μm, (D-F) 25 μm.
We have previously shown high baseline LPS activity in sera of Finnish patients with T1D to be
associated with the progression of DN (Nymark et al., 2009). To study the potential antiapoptotic role
of PDK1 in LPS-induced podocyte injury, we subjected cultured podocytes to sera from
normoalbuminuric  T1D patients  with  either  high  (0.41  EU/ml)  or  low (0.20  EU/ml)  LPS activity.
Clinical characteristics of normoalbuminuric patients with T1D with low or high serum LPS activity
are shown in Table 3. PDK1 expression was found to be lower and apoptosis induced in human
podocytes exposed to sera with high LPS activity for 72 h when compared to cells treated with sera
with  low  LPS  activity  (Study  II,  Figure  2).  High  glucose  treatment  that  has  previously  shown  to
induce podocyte apoptosis (Liu et al., 2013;Susztak et al., 2006), also downregulated PDK1
expression compared to cells cultured in normal glucose or in high mannitol (osmolality control)
(Study II, Supplementary Figure S1). Interestingly, blood glucose values were similar in patients with
low and high serum LPS activity, indicating that high glucose did not contribute to reduced PDK1
expression or increased apoptosis.
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Table 3. Patient characteristics. All patients were males. Normoalbuminuria was defined as urinary
albumin excretion rate <30 mg/24 h. LPS, lipopolysaccharide; HbA1c, hemoglobin A1c; HDL, high-
density lipoprotein; Duration, duration of diabetes.
LPS
Low High
(n=6) (n=6)
Age (years) 34.8 ± 3.3 33.2 ± 6.7
Duration (years) 13.8 ± 2.7 14.2 ± 3.9
LPS (EU/ml) 0.20 ± 0.01 0.41 ± 0.04*
Triglycerides (mmol/L) 1.0 ± 0.9 1.2 ± 0.6
HbA1c (%) 7.9 ± 0.8 7.7 ± 0.2
HDL-cholesterol 1.32 ± 0.12 1.34 ± 0.19
Glucose (mmol/L) 8.63 ± 2.19 5.83 ± 1.08
* p < 0.001, Student’s t-test.
5.2.2. Knockdown of PDK1 increases apoptosis, inhibits antiapoptotic- and stimulates
proapoptotic pathways in cultured human podocytes
PDK1 was knocked down in cultured podocytes in order to study the antiapoptotic role of PDK1.
Two  different  lentiviral  small  hairpin  RNAs  (shRNAs)  were  used  and  both  lowered  PDK1  level
compared  to  podocytes  infected  with  empty  vector  (Study  II,  Figure  3A  and  B).  Apoptosis  was
increased from 6% in podocytes infected with the empty vector to 22-27% in podocytes infected with
PDK1 shRNAs as shown by increase in Annexin V labeled cells in flow cytometry (Figure 10 and
Study II, Figure 3C).
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Figure 10. Knockdown of PDK1 increases apoptosis in cultured human podocytes. A: Flow
cytometry of podocytes stained with Annexin V shows that PDK1 knockdown increases podocyte
apoptosis compared to podocytes infected with empty vector (EV). The experiments were performed
three times with three replicates in each experiment. The bars (A) show the mean expression in
arbitrary units (error bars STDEV). **p < 0.01, ***p < 0.001, Student's t-test.
Downregulation of PDK1 also altered the phosphorylation of apoptosis-related kinases, Akt and
p38MAPK. Depletion of PDK1 reduced the phosphorylation level of Akt on S437, and increased the
activation of the proapoptotic p38 MAPK pathway by inducing phosphorylation of p38 (Study II,
Figure 3F,G,I and J). PDK1 knockdown also decreased the level of antiapoptotic BCL-2 and
increased the level of proapoptotic BAX indicating that the intrinsic apoptotic pathway is also
involved in the antiapoptotic PDK1 pathway in podocytes (Study II, Figure 3H and K).
5.2.3. PDK1 expression is downregulated in the glomeruli of diabetic Zucker rats and
patients with T2D, and in podocyte injury models in vitro
Next, we analyzed whether PDK1 expression is reduced in the glomeruli of insulin resistant obese
Zucker rats (Chua et al., 1996). PDK1 expression was found to be lower in obese Zucker rat glomeruli
in both 12 and 40 weeks old rats when compared to lean controls (Study II, Figure 4A,B,D and E).
There  was  no  significant  apoptosis  in  12  weeks  old  obese  rat  glomeruli  (Study  II,  Figure  4C).  40
weeks old rats showed increased glomerular apoptosis (Study II, Figure 4F). PDK1 expression was
also lower in patient glomeruli with T2D compared to controls (Study II, Figure 4G,H and I). The
patients with diabetes did not have clinical nephropathy, and histopathological analysis revealed no
signs of DN.
We also investigated the expression of PDK1 in podocyte injury models in vitro using PA. PA is a
toxin  that  induces  experimental  minimal  change  nephrosis  in  rats  (Marshall  et  al.,  2006).  PA-
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treatment decreased the expression level of PDK1 and induced apoptosis 48 hours after exposure
(Figure 11).
Figure 11. PA-treatment downregulates PDK1 expression and induces apoptosis in cultured human
podocytes. A: Representative immunoblot for PDK1 and caspase-3 after PA-treatment. Tubulin is
included as a loading control. B: Quantification of PDK1 after PA-treatment shows a decrease in
PDK1 expression. C: Quantification of caspase-3 after PA-treatment shows a decrease in caspase-3
expression level suggesting induction in podocyte apoptosis. D: Flow cytometry of cultured human
podocytes stained with annexin V and 7-AAD double labeling, where annexin V is used as an
apoptosis and 7-AAD as a necrosis marker, confirms that PA-treatment increase podocyte apoptosis.
The experiments were performed three times with three replicates in each experiment. The bars (B,
C and D) show the mean expression in arbitrary units (error bars STDEV). *p < 0.05, **p < 0.01,
***p < 0.001, Student's t-test.
5.2.4. Inhibition of the TLR pathway prevents LPS-induced downregulation of PDK1,
induction of apoptosis in vivo and in vitro, and podocyte foot process widening
Toll-like  receptors  (TLRs),  including  TLR4,  which  acts  as  a  receptor  for  LPS,  are  known  to  be
expressed in podocytes (Banas et al., 2008;Poltorak et al., 1998;Srivastava et al., 2013). To study,
whether  inhibition  of  the  TLR  pathway  could  reduce  LPS-induced  downregulation  of  PDK1  and
apoptosis of podocytes, cultured human podocytes were treated with GIT27 before addition of LPS
(100  ng/ml)  to  the  media.  GIT27  is  an  active  immunomodulatory  agent  that  inhibits  TLR4  and
TLR2/6 signaling pathways. GIT27 and LPS co-treatment prevented LPS-induced downregulation of
PDK1 and induction of podocyte apoptosis (Study II, Figure 5).
To confirm that inhibition of the TLR pathway reduces the LPS-induced apoptosis and dowregulation
of PDK1 expression in vivo, we used LPS to induce podocyte injury and proteinuria in BALB-C mice.
Mice  were  treated  with  either  GIT27  or  its  vehicle  24  h  prior  to  and  2  h  after  LPS  challenge.
Albuminuria, PDK1 expression and kidney morphology were analyzed 24 h after the LPS challenge.
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LPS increased urinary albumin excretion, decreased glomerular expression of PDK1 and increased
tubular apoptosis (Study II, Figure 6). GIT27 treatment prevented the decrease in the expression of
PDK1 and the increase in apoptosis (Study II, Figure 6). GIT27 also decreased urinary albumin
excretion, but this did not reach statistic significance. Electron microscopy (EM) revealed irregular
widening of the podocyte foot processes in the LPS-treated mice when compared to control mice and
mice treated with LPS and GIT27 (Study II, Figure 7A-E). Confirming the protective effect of GIT27,
we found that the level of slit diaphragm protein podocin, essential for podocyte survival (Jefferson
et al., 2008), was also reduced in LPS-treated mice (Study II, Figure 7E and F). LPS-induced decrease
of podocin was prevented by GIT27 co-treatment.
5.2.5. Inhibition of the TLR pathway restores the expression of PDK1 and reduces podocyte
apoptosis induced by sera from T1D patients with high LPS activity
To confirm that high serum LPS activity in T1D patients causes downregulation of PDK1, we treated
cultured human podocytes with GIT27 for 2 h before exposing the cells to the media with sera from
normoalbuminuric  T1D  patients  with  high  LPS  activity.  As  above,  serum  with  high  LPS  activity
downregulated PDK1 expression and induced podocyte apoptosis when compared to cells treated
with the sera with low LPS activity. Co-treatment with GIT27 was able to prevent the downregulation
of PDK1 and induction of apoptosis induced by high LPS activity (Study II, Figure 8). The data
indicate that high LPS activity downregulates PDK1 expression and induces apoptosis in podocytes,
and this can be prevented with GIT27 co-treatment (Study II, Figure 8).
5.3. Study III: Cyclin-dependent kinase 2 protects podocytes from apoptosis
5.3.1. CDK2 is downregulated in the glomeruli of diabetic rats, after high glucose treatment
and in podocyte injury models in vitro
CDK2, a protein that is believed to play an essential role in cell cycle, is widely expressed in human
tissues. Although Hiromura et al. (2001) showed by Western blot that CDK2 is expressed in
proliferating and differentiated mouse podocytes in vitro (Hiromura et al., 2001), its localization and
function in podocytes remains unclear. Therefore, we wanted to first confirm its expression in
glomeruli by immunoblotting of isolated rat glomerular and tubular fractions and found that CDK2
is expressed in both glomeruli and tubules (Study III, Figure 1A). Localization of CDK2 in podocytes
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was studied by immunofluorescence microscopy of cultured human podocytes, indicating that CDK2
is  concentrated  in  the  nuclei  in  podocytes  (Study  III,  Figure  1B).  We  used  immunofluorescense
staining of perfused mouse kidney paraffin sections to confirm CDK2 expression in the nuclei of
glomerular podocytes (Figure 12 and Study III, Figure 1D-I).
Figure 12. CDK2 is expressed in glomerular podocytes. (A-C)  Double labeling of CDK2 (A) and
nephrin (B) indicates that CDK2 is expressed in the nuclei (arrows) of podocyte as visualized in the
merged image (C). (A-C) Perfused mouse kidney paraffin sections were labeled with anti-CDK2 and
anti-nephrin IgGs, and examined by confocal microscopy. Scale bar: 25 μm.
To  study  the  role  of  CDK2  in  diabetes  and  DN,  we  studied  the  expression  level  of  CDK2  in  the
glomeruli of insulin resistant obese Zucker rats and found that the expression level of CDK2 was
lower in both 12 weeks and 40 weeks old Zucker rats when compared to lean controls (Study III,
Figure 2). Blood glucose and urinary values of Zucker rats are described in Table 3.
Next, we investigated the expression of CDK2 in podocyte injury models in vitro using PA and LPS.
LPS is known to induce septic like symptoms and proteinuria in mice and rats (Reiser et al.,
2004;Remick et al., 2000). Both PA- and LPS-treatments decreased the expression level of CDK2
and induced apoptosis 48 hours after exposure (Study III, Figure 3). Treatment of human podocytes
with high glucose (72 h) also downregulated CDK2 expression compared to cells cultured in normal
glucose.
5.3.2. Inhibition of the TLR pathway prevents downregulation of CDK2 and induction of
podocyte apoptosis induced by LPS
Next we studied whether TLR pathway inhibitor, GIT27 can also rescue LPS-induced downregulation
of CDK2. LPS-treatment reduced the expression of CDK2 and induced apoptosis in cultured human
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podocytes and GIT27 co-treatment was able to prevent both the downregulation of CDK2 and
induction of apoptosis induced by LPS-treatment (Study III, Figure 4A-C).
To study whether T1D patient serum with high LPS activity also reduces the expression of CDK2,
we treated  cultured  human podocytes  with  sera  from normoalbuminuric  patients  with  high  or  low
LPS activity with or without GIT27 co-treatment (patient data is described in Table 4). Treatment
with human sera with high LPS activity decreased the expression level of CDK2 and induced
apoptosis (Study III, Figure 4D-F). Co-treatment with GIT27 prevented LPS-induced downregulation
of CDK2 expression and induction of apoptosis confirming that CDK2 downregulation is mediated
by endotoxins in treatment with human serum with high LPS activity (Study III, Figure 4D-F).
5.3.3. TLR Pathway blockage restores the glomerular expression of CDK2 and prevents
podocyte foot process widening induced by LPS in mice in vivo
To confirm that LPS induced the downregulation of CDK2 and to study whether LPS-induced
dowregulation of CDK2 expression can be rescued by TLR pathway inhibition in vivo, we used LPS
with or without GIT27 co-treatment in BALB-C mice as described in Study II. LPS decreased also
the expression of CDK2 in mouse kidneys, and in mouse glomeruli as visualized by immunoblotting
and immunohistochemistry, respectively (Study III, Figure 5A and B). In addition, co-treatment with
GIT27  prevented  downregulation  of  CDK2  (Study  III,  Figure  5A  and  B).  GIT27  treatment  also
prevented the increase in LPS induced apoptosis in the mouse kidneys, but this did not reach statistical
significance due to due to individual variation in the treatment groups (Figure 13).
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Figure 13. Inhibition of the TLR pathway prevents LPS-induced apoptosis in mouse kidneys. A:
Representative immunoblot for cleaved caspase-3 in control, LPS-treated and LPS- and GIT27-
treated mouse kidney cortical lysates. Tubulin is included as a loading control. B: Quantification of
cleaved caspase-3 in mouse kidney cortical lysates shows that co-treatment of mice with LPS and
GIT27 prevents LPS-induced apoptosis, although this did not reach statistical significance (n= 6 per
treatment group).
5.3.4. Knockdown of CDK2 increases apoptosis, inhibits the antiapoptotic and stimulates the
proapoptotic pathways in cultured human podocytes
CDK2 was knocked down in cultured podocytes using two different lentiviral small hairpin RNAs
(shRNAs) in order to confirm the antiapoptotic role of CDK2 in podocytes. Both shRNA constructs
lowered CDK2 protein level up to 85% 48 h after infection compared to podocytes infected with
empty vector (Study III, Figure 6A and B). Knockdown of CDK2 induced podocyte apoptosis, as
shown by flow cytometry with annexin V labeling, when compared to podocytes infected with empty
vector (Figure 14 and Study III, Figure 6C).
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Figure 14. Knockdown of CDK2 increases apoptosis in cultured human podocytes. A: Flow
cytometry of podocytes stained with Annexin V shows that CDK2 knockdown increases podocyte
apoptosis compared to podocytes infected with empty vector (EV). The experiments were performed
three times with three replicates in each experiment. The bars (A) show the mean expression in
arbitrary units (error bars STDEV). **p < 0.01, Student's t-test.
CDK2 knockdown also had an effect on the molecular pathways involved in apoptosis, as
phosphorylation of Akt was reduced and phosphorylation of p38MAPK was induced after CDK2
knockdown (Study III, Figure 7A-D). Furthermore, CDK2 knockdown also reduced the expression
level of antiapoptotic BCL-2 and increased the expression level of proapoptotic BAX indicating that
CDK2 influences the intrinsic apoptotic pathway in podocytes (Study III, Figure 7E and F).
5.3.5. CDK2 knockdown reduces PDK1 expression and knockdown of PDK1 reduces CDK2
expression
Since downregulation of both PDK1 and CDK2 induced podocyte apoptosis and reduced Akt
phosphorylation, we next hypothesized that both of these proteins are activators of the Akt cell
survival pathway and they are linked to each other. To test this hypothesis, we knocked down either
CDK2 or PDK1 using lentiviral shRNAs. CDK2 knockdown reduced the expression of PDK1
suggesting that CDK2 affects the PI3K/Akt –mediated cell survival pathway by regulating PDK1
expression (Study III, Figure 8A and B). Knockdown of PDK1, in turn, reduced the expression of
CDK2 suggesting a regulatory loop between CDK2 and PDK1 (Study III, Figure 7C and D).
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6. DISCUSSION
6.1. Function of SHIP2 in Akt signaling pathway and apoptosis in podocytes
We identified SHIP2 as a new interaction partner of CD2AP, an adaptor protein critical for podocyte
function in maintaining the GFB (Shih et al., 1999). CD2AP is essential for podocyte function, since
damage to CD2AP not only affects the function of SDs, but also directly damages the podocyte
cytoskeleton leading to pathological changes such as podocyte loss (Schwarz et al., 2001). In addition,
CD2AP expression was decreased in albumin-induced podocyte apoptosis (He et al., 2011). CD2AP
also stimulates PI3K-dependent Akt signaling pathway (Huber et al., 2003), and lack of CD2AP
enhances the activation of the proapoptotic p38 MAPK pathway by TGF-ß1 (Schiffer et al., 2004).
Since SHIP2 is a negative regulator of insulin signaling in adipocytes (Dyson et al., 2005), our finding
showing that SHIP2 interacted with CD2AP, suggest that SHIP2 might be involved in Akt dependent
insulin signaling also in podocytes. Although SHIP2 has previously shown to be involved in the
regulation of food intake and expressed in elevated levels in adipose tissue, skeletal muscle and in
the hypothalamus of db/db mice (Ichihara et al., 2013), its expression and function in the kidney has
not been studied previously.
SHIP2  is  a  lipid  phosphatase  belonging  to  the  inositol  5-phosphatase  family  acting  on
phosphoinositol(3,4,5)trisphosphate (PI(3,4,5,)P3)  (Dyson  et  al.,  2005).  SHIP2  hydrolyses  the  5-
position phosphate from PI(3,4,5,)P3 to form phosphoinositol(3,4)biphosphate (PI(3,4,)P2) and
therefore negatively regulates the PI3K pathway (Blero et al., 2001;Pesesse et al., 1997;Taylor et al.,
2000;Wisniewski et al., 1999). In addition, SHIP2 has been reported to be phosphorylated in response
to numerous growth factors including insulin (Habib et al., 1998;Ishihara et al., 1999;Muraille et al.,
1999;Wisniewski et al., 1999). Since podocytes have shown to be insulin responsive cells (Coward
et al., 2005) and SHIP2 was reported to negatively regulate PI3K pathway, the major cell survival
pathway in podocytes (Huber et al., 2003), we hypothesized that SHIP2 would be involved in Akt
signaling pathway and apoptosis also in podocytes.
First, SHIP2 was found to be expressed in glomerular podocytes. In addition, the intracellular
interaction of CD2AP and SHIP2 was confirmed. The catalytic activity of SHIP2 has been suggested
to be mediated by enhanced tyrosine phosphorylation (Batty et al., 2007;Pesesse et al., 2001),
however, Edimo et al. (2012) suggested, based on other publications, that several key properties of
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SHIP2 are regulated by serine/threonine phosphorylation (Edimo et al., 2012). In addition to the
catalytic activation of SHIP2, it has been shown to be relocated to the plasma membrane upon growth
factor stimulation (Pesesse et al., 2001). Our data demonstrate that SHIP2 is translocated to the
plasma membrane in response to insulin in podocytes. However, the interaction of CD2AP and SHIP2
was not dependent on insulin stimulus. CD2AP bound only to the non-tyrosine-phosphorylated form
of SHIP2 independently of insulin stimulation suggesting that the interaction of CD2AP and SHIP2
is not predominantly due to regulation of insulin signaling.
In cultured human podocytes, overexpression of SHIP2 led to decreased Akt phosphorylation.
Supporting our finding, SHIP2 has been shown to downregulate insulin-induced Akt activation in
adipocytes (Wada et al., 2001). Previous finding, showing that overexpression of SHIP2 in Chinese
hamster ovary cells overexpressing the insulin receptor led to a decrease of the insulin-dependent
PI(3,4,5)P3 production as well as decrease in Akt and MAPK activation (Blero et al., 2001) together
with our results indicating, that SHIP2 overexpression downregulates the PI3K pathway in podocytes,
suggests that SHIP2 may be involved in the development of impaired insulin signaling in podocytes.
Impaired insulin response might be involved in podocyte loss in DN, since Akt phosphorylation has
previously been shown to act as a survival signal in podocytes and to protect them from apoptosis
(Huber et al., 2003). Given the importance of Akt signaling pathway in cell survival, and since SHIP2
reduced Akt signaling in podocytes, we studied the role of SHIP2 in podocyte apoptosis. Indeed, in
addition to decreased Akt activation, overexpression of SHIP2 also increased podocyte apoptosis,
suggesting that SHIP2 could contribute to development of the glomerular injury by downregulating
the Akt survival pathway.
SHIP2 expression in podocyte injury model in vitro was studied to confirm the involvement of SHIP2
in podocyte apoptosis. Recently it was shown that overexpression of angiopoietin-like3 (Angptl3), a
protein that induces F-actin arrangement in podocytes (Lin et al., 2013), accelerated the PA-induced
podocyte loss in vitro (Dai et al., 2015). Since SHIP2 overexpression also induced podocyte apoptosis
and SHIP2 has previously shown to regulate the maintenance and remodeling of actin structures in
HeLa cells (Prasad and Decker, 2005), we studied whether SHIP2 expression increases in PA-induced
podocyte injury model. PA is a podocyte toxin used in rats to induce experimental minimal change
disease progressing to FSGS (Marshall et al., 2006). We observed that SHIP2 expression and
podocyte apoptosis were upregulated in PA-induced podocyte injury in vitro. Wang et al. (2015)
demonstrated recently that VEGF promotes podocyte survival against PA-induced apoptosis by
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enhancing PI3K/Akt pathway (Wang et al., 2015). The increased expression of SHIP2 in PA-induced
podocyte injury together with data showing that the SHIP2 overexpression downregulates the
PI3K/Akt pathway in podocytes, implicates that upregulation of SHIP2 could be one possible
mechanism inducing podocyte apoptosis in podocyte injury.
In addition to cell survival, Akt signaling is involved in glucose uptake, where PI3K increases
intracellular PI(3,4,5,)P3 at the plasma membrane leading to the activation of Akt and PDK1, which
is required for insulin-induced action such as translocation of GLUT4 to the plasma membrane
(Dugani and Klip, 2005;Farese et al., 2005). Activation of PI3K/Akt signaling pathway is involved
in the regulation of insulin signaling as Akt2 knock-out mice are insulin resistant and diabetic (Cho
et al., 2001;Garofalo et al., 2003;Canaud et al., 2013). Previous discoveries showing that SHIP2 is
expressed in elevated levels in skeletal muscle and adipose tissue of db/db mice (Hori et al., 2002),
combined with our results showing decreased Akt signaling after SHIP2 overexpression, suggests
that SHIP2 might be involved also in glucose uptake in podocytes
6.2. PDK1 and CDK2 regulate PI3K/Akt cell survival pathway and apoptosis in podocytes
Given the pivotal role of the PI3K-dependent Akt signaling pathway in the regulation of cell survival,
we next studied molecules known to be involved in the modulation of its activation, both upstream
and downstream of Akt. We concentrated on PDK1, a serine/threonine kinase that functions
downstream of PI3K and upstream of Akt and is known to act  as a major regulatory point in Akt
signaling (Keledjian et al., 2012) and CDK2, a S-phase cyclin-dependent kinase, that has been shown
to be phosphorylated by Akt in vitro in 293T cells (Maddika et al., 2008). In addition, in HeLa cells,
CDK2 was shown to promote the activation of Akt by phosphorylating residues S477 and T479 under
cell cycle progression (Liu et al., 2014).
In podocytes, the expression and function of PDK1 had not been studied before. First, PDK1 was
confirmed to be expressed in glomerular podocytes. Since PDK1 was shown to be involved in
regulation of Akt signaling (Keledjian et al., 2012), we hypothesized that it may be involved in the
regulation of apoptosis in podocytes.  Previously, it has been shown that PDK1 knockout mice die in
utero, but mice that lack PDK1 specifically in the pancreatic β cells develop progressive
hyperglycemia as a result of the loss of islet mass (Hashimoto et al., 2006;Lawlor et al., 2002).
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Even though Hiromura et al. (2001) showed that CDK2 is expressed in both proliferating and
differentiated mouse podocytes in vitro, its localization and function in podocytes remains unclear.
We found that CDK2 is expressed in glomerular podocytes, although previous studies have mainly
shown negligible  expression  of  CDK2 in  healthy  glomerulus  (Shankland  et  al.,  1997;Wang et  al.,
2004). The difference in CDK2 expression in previous studies and in our study may be due to different
experimental conditions, or antibodies used. In addition, previous studies addressing the role of
CDK2 in the kidney have concentrated on proliferative podocyte injury models. In experimental
glomerulonephritis, where podocytes re-enter the cell cycle and start to proliferate, inhibition of
CDK2 has been shown to improve renal function by inhibiting proliferation of podocytes (Griffin et
al.,  2005).  Inhibition  of  CDK2  by  roscovitine  has  also  been  shown  to  decrease  mesangial  and
glomerular endothelial cell proliferation in passive Heymann nephritis, a model of membranous
nephropathy, without aggravating podocyte damage (Milovanceva-Popovska et al., 2005). Since
mature podocytes are terminally differentiated and therefore have a limited capacity to proliferate,
the role of CDK2 in healthy, nonproliferating podocytes and nonproliferative glomerular diseases,
such as DN, remains unclear. Furthermore, CDK2 activity is regulated by several factors, as CDK2
is controlled by cyclin-dependent kinase inhibitors (Hiromura et al., 2001;Shankland et al., 1997) and
in cell cycle, CDK2 is activated by complex formation with cyclin E, or A (Bartova et al., 2004).
To study whether PDK1, or CDK2 are involved in the regulation of PI3K-dependent Akt signaling
pathway and apoptosis in podocytes, we knocked down either PDK1 or CDK2 in cultured human
podocytes. Previous studies have shown that in addition to Akt (Bridgewater et al., 2005;Chen et al.,
2009) and 38p MAPK (Chen et al., 2009) pathways, BCL-2 and BAX are involved in podocyte
apoptosis (Lee et al., 2009;Sun et al., 2009a). Indeed, knockdown of either PDK1, or CDK2 in
cultured human podocytes decreased the activation of antiapoptotic Akt and the expression of BCL-
2, and in addition, stimulated the proapoptotic p38 MAPK activation and increased the expression of
BAX.  Since  knockdown  of  either  PDK1  or  CDK2  led  also  to  an  increase  in  apoptosis,  we
hypothesized that both PDK1 and CDK2 protect podocytes from apoptosis by stimulating the PI3K-
dependent Akt signaling pathway.
Supporting our data for the role of PDK1 as an antiapoptotic protein, inhibition of the Akt pathway
with a specific PDK1 inhibitor has previously been shown to induce apoptosis of human mast cells
(Sawamukai et al., 2007). In addition, induction of PDK1 activity has been shown to decrease
apoptosis by activating Akt in intestinal epithelial cells (Keledjian et al., 2012). Supporting our
finding for CDK2 as protein protecting podocytes from apoptosis, inhibition of CDK2 in HeLa cells
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has been shown to decrease Akt phosphorylation (Liu et al., 2014). In line with this, CDK2 associated
with cyclin A2 and Akt phosphorylation was inhibited in olfactory bulbs of brain-specific cyclin A2
knockout mice leading to increased activation of caspase-3 and cellular apoptosis (Liu et al., 2014).
To further confirm the role of PDK1 and CDK2 in podocyte apoptosis, we used PA-induced in vitro
podocyte injury model. PA was previously shown to increase BAX and decrease BCL-2 expression
in cultured mouse podocytes (Remick et al., 2000). We observed that treatment of podocytes with the
toxin PA induced podocyte apoptosis and downregulated both PDK1 and CDK2, suggesting that both
PDK1 and CDK2 have a role in PA-induced podocyte apoptosis.
Since PA is a toxin used only in experimental conditions to induce experimental minimal change
disease or FSGS (Marshall et al., 2006), we wanted to study the expression of PDK1 and CDK2 also
in conditions closer to diabetic diseases in vivo. Since increased podocyte apoptosis has previously
been shown in vitro after high glucose-treatment (Susztak et al., 2006), and also in vivo in both Akita
mice with T1D and in db/db mice with T2D (Susztak et  al.,  2006),  we used high glucose to study
whether PDK1 and CDK2 are involved in podocyte injury induced by high glucose. In cultured
podocytes,  high glucose treatment decreased both PDK1 and CDK2 expression (Studies I  and II).
Wang et al. (2014) showed recently, that high glucose decreased BCL-2 and increased BAX protein
level and induced podocyte apoptosis, and knockdown of Akt accelerated these effects (Wang et al.,
2014). In the same study, high glucose induced podocyte apoptosis was prevented by PI3K/Akt
pathway activation (Wang et al., 2014). In addition, Lee et al. (2009) demonstrated that BAX and
active caspase-3 expressions were upregulated in diabetic rat glomeruli and in cultured mouse
podocytes treated with high glucose (Lee et al., 2009). Our findings together with these recent
discoveries suggest that PDK1 and CDK2 may mediate glucose-induced podocyte apoptosis through
PI3K/Akt pathway.
In addition to PA- and high glucose treatment, LPS-treatment has shown to be involved in the
development of albuminuria and podocyte apoptosis. In fact, LPS-treatment of mice was shown to
lead to general inflammation and diabetes and induction of albuminuria (Cani et al.,
2007;Cunningham et al., 2000;Reiser et al., 2004).We treated cultured podocytes with human sera
with high LPS, since it has been shown that high serum LPS activity in normoalbuminuric patients
with T1D predicts the progression of DN (Nymark et al., 2009). Treatment of podocytes with sera
with high LPS activity from patients with T1D downregulated both PDK1 and CDK2, and induced
podocyte apoptosis indicating that these proteins may have a role in maintaining normal podocyte
59
function, since incidence of bacterial infections in Finnish patients with T1D has been shown to
correlate with the severity of DN (Simonsen et al., 2015). However, there might be some other factors
in human sera in addition to LPS that could contribute to downregulation of PDK1 and CDK2.
Nevertheless, high glucose did not contribute to increased apoptosis or decreased PDK1, or CDK2
expression in treatment with human sera with high LPS, since blood glucose values were similar in
patients with low and high serum LPS. In addition to human sera with high LPS activity, treatment
with exogenously added LPS decreased CDK2 and PDK1 expressions and induced podocyte
apoptosis. In line with this, administration of LPS to mice in vivo also reduced the levels of CDK2
and PDK1 in glomeruli and induced apoptosis in the kidneys. LPS-treatment of mice induced
podocyte foot process widening and albuminuria.
To find possible treatment options for LPS-induced podocyte injury, we blocked the TLR4 pathway
since LPS binds to TLR4 also in podocytes (Banas et al., 2008;Reiser et al., 2004;Srivastava et al.,
2013). Mice that lack TLR4 (Hoshino et al., 1999), or mice in which TLR4 is mutated (Poltorak et
al., 1998;Qureshi et al., 1999), are low responders to LPS. We used immunomodulatory agent GIT27
to inhibit the TLR4 pathway. GIT27 treatment prevented the LPS-induced and high serum LPS
activity induced downregulations of CDK2 and PDK1 both, in vitro and in vivo. GIT27 treatment
also prevented LPS-induced apoptosis in vitro and in vivo and podocyte foot process effacement in
LPS-treated mice. Due to the non-nephrotoxic feature of GIT27 (Cha et al., 2013;Min et al., 2014), it
may  be  clinically  potential  in  the  treatment  of  DN.  Since  GIT27  is  known  to  inhibit  also  TLR2
(Stojanovic et al., 2007) that is expressed in podocytes (Srivastava et al., 2013) and linked with
diabetes (Dasu et al., 2008;Dasu and Jialal, 2011;Devaraj et al., 2008), GIT27 might protect
podocytes also by inhibition of the TLR2 pathway in addition to the TLR4 pathway.
6.3. SHIP2, PDK1 and CDK2 in T2D in vivo
Since SHIP2, PDK1 and CDK2 were found to be involved in the regulation of Akt cell survival
pathway and podocyte apoptosis in vitro, we further studied these proteins in animal models and
human patients with T2D. We found SHIP2 expression to be slightly increased in glomeruli of db/db
mice, a known model of insulin resistance characterized by hyperphagia and obesity (Chua et al.,
1996). Insulin resistance has been previously shown in podocyte cell line derived from db/db mice
compared to podocyte line from control mice (Tejada et al., 2008), and SHIP2 has been linked to
insulin resistance and diabetes in SHIP2 deficient mice (Clement et al., 2001). Since SHIP2 was
upregulated in glomeruli of db/db mice and Suztak et al. (2006) showed increase in podocyte
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apoptosis in db/db mice before increase in urinary albumin excretion (Susztak et al., 2006), SHIP2
may be one of the factors inducing the development of insulin resistance and injury of podocytes in
these mice.
We further observed that SHIP2 expression was increased and PDK1 and CDK2 decreased in
glomeruli of insulin resistant obese Zucker rats already at 12 weeks of age compared to lean controls.
Interestingly, although it has been previously reported that Zucker rats do not develop proteinuria or
glomerular apoptosis at 12 weeks of age (Cani et al., 2007;Coimbra et al., 2000;Dasu et al., 2008;Dasu
and Jialal, 2011), we saw trend in apoptosis already in 12 week old Zucker rats. Since these rats had
not yet developed proteinuria at 12 weeks of age, and podocytes we saw trend in apoptosis already in
12 weeks old Zucker rats, although this did not reach statistical significance are terminally
differentiated cells, even a small increase in apoptosis could contribute to glomerular injury.
Therefore SHIP2, PDK1 and CDK2 might be associated with the development of podocyte apoptosis
already at early stage. Further supporting our findings, glomerular apoptosis was shown in the kidneys
of patients with DN, already in early nephropathy (Verzola et al., 2007), and PDK1 was
downregulated in the glomeruli of patients with T2D who had not yet developed clinical nephropathy.
More data is needed to conclude how Akt signaling pathway is regulated in podocytes, however, our
data demonstrate that SHIP2 downregulates PI3K-dependent Akt signaling pathway, PDK1, and also
CDK2 activates Akt. Furthermore, knockdown of PDK1 reduced CDK2 expression, and knockdown
of CDK2 reduced PDK1 expression suggesting a regulatory loop between these two proteins. Given
the central role of the PI3K-dependent Akt signaling pathway in regulating cell survival, we
concluded that SHIP2, PDK1 and CDK2 regulate apoptosis in podocytes by modulating the activity
of the PI3K-dependent Akt signaling pathway (Figure 15).
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Figure 15. PI3K-dependent Akt signaling in podocyte apoptosis. PI3K: phosphoinositide 3-kinase;
PDK1: 3-phosphoinositide dependent kinase 1; CDK2: cyclin-dependent kinase 2; CD2AP: CD2-
associated protein; SHIP2:SH2-domain-containing inositol polyphosphate 5-phosphate 2; PIP2:
phosphoinositol(4,5)biphosphate; PIP3: phosphoinositol(3,4,5)trisphosphate; PIP2b:
phosphoinositol(3,4)biphosphate.
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7. SUMMARY AND FUTURE PERSPECTIVES
The  studies  in  this  thesis  provide  new  discoveries  in  regulation  of  podocyte  apoptosis  in  the
development of DN, concentrating on three molecules expressed in podocytes, SHIP2, PDK1 and
CDK2. Biochemical methods were used for characterization of protein-protein interactions. In
addition, cell culture experiments and diabetic and proteinuric animal models were used to study the
expression and function of SHIP2, PDK1 and CDK2 in podocyte apoptosis.
Study  I  demonstrated  that  SHIP2  is  expressed  in  glomerular  podocytes  and  that  SHIP2  is  an
interaction partner of CD2AP. The interaction of CD2AP and SHIP2 was not predominantly due to
regulation of insulin signaling, since CD2AP bound only to the non-tyrosine-phosphorylated form of
SHIP2 independently of insulin stimulation. Overexpression of SHIP2 in cultured human podocytes
downregulated insulin signaling by reducing Akt phosphorylation and induced apoptosis. The
expression of SHIP2 was found to be upregulated in the glomeruli of diabetic Zucker rats prior to the
development of albuminuria suggesting a role for SHIP2 in the development of podocyte injury. In
addition, PA-treatment of podocytes upregulated SHIP2 expression and induced apoptosis. In
conclusion, SHIP2 promotes impaired insulin signaling and podocyte apoptosis by downregulating
the Akt signaling pathway. However, it is still unknown whether LPS-treatment upregulates SHIP2,
since LPS induces podocyte apoptosis. In addition, further studies are needed to define whether
downregulation of SHIP2 using shRNA lentiviral infections, or inhibition of its activity using specific
SHIP2 inhibitor either in podocytes in vitro, or diabetic animal models in vivo can protect podocytes
from developing insulin resistance and apoptosis. Therefore, in the future, inhibition of SHIP2 could
produce significant benefits in treatment of diabetes and its kidney complications.
Studies  II  and  III  showed  that  glomerular  podocytes  express  PDK1  and  CDK2.  In  addition,  both
PDK1 and CDK2 were downregulated in diabetic rats before the onset of proteinuria, suggesting that
PDK1 and CDK2 are associated with podocyte injury and development of DN. Supporting these
results,  PDK1 was also downregulated in the glomeruli  of patients with T2D prior to the onset of
proteinuria. Further supporting our data, treatment of podocytes with high glucose suppressed PDK1
and CDK2 expression. In addition, treatment of human podocytes with sera from normoalbuminuric
T1D patients with high LPS activity reduced both PDK1 and CDK2 expression and induced
apoptosis. In line with this, LPS-treatment in vitro and in vivo downregulated both PDK1 and CDK2,
and induced apoptosis, which was prevented by inhibition of the TLR signaling pathway using
63
GIT27. Knockdown of either PDK1 or CDK2 in cultured podocytes increased apoptosis, and
downregulated Akt phosphorylation, BCL-2 protein and upregulated the proapoptotic p38 MAPK
pathway and BAX expression confirming their role in podocyte apoptosis. In addition, knockdown
of PDK1 downregulated CDK2 and CDK2 knockdown downregulated PDK1 expression suggesting
a regulatory loop between these proteins. The results of these studies suggest that PDK1 and CDK2
protect podocytes from apoptosis by activating the Akt survival pathway, and that LPS-induced
podocyte injury can be prevented by blocking the TLR pathway and by preventing downregulation
of PDK1 and CDK2. Still, more investigations are required to define the specific role of PDK1 and
CDK2 in regulating podocyte apoptosis. For instance, would co-treatment with high glucose and LPS
enhance the downregulation of PDK1 and CDK2 and would knockdown of PDK1 or CDK2 in
diabetic animal models in vivo increase  the  susceptibility  to  glomerular  diseases.  In  addition,  it  is
unknown whether overexpression of PDK1 or CDK2 can prevent high glucose, PA-, or LPS-induced
podocyte apoptosis, and whether podocyte-specific overexpression of PDK1 or CDK2 in diabetic
animal models can prevent the progression of the disease. In the future, factors that upregulate PDK1
and/or CDK2 in podocytes could be a promising treatment strategy for diabetic kidney disease.
Since the LPS-treatment used in the studies in this thesis was a short-term and high concentration
treatment, that causes sepsis and albuminuria, it would be interesting to study the expression of PDK1
and CDK2 in mice with a long-term and low concentration LPS-treatment, where they develop
diabetes in addition to albuminuria. Also, whether long-term GIT27 administration prevents LPS-
induced diabetes and possible downregulation of PDK1 and CDK2 in these mice. In addition, since
PDK1 and CDK2 where downregulated by high glucose treatment and were involved in the regulation
of Akt signaling pathway, that also is involved in the regulation of insulin signaling, future
investigations could study the role of PDK1 and CDK2 in insulin signaling and insulin resistance in
podocytes.
Taken together, pathogenesis of DN is multifactorial and several genetic and environmental
components might contribute to its development and progression. However, the precise mechanisms
remain unknown. It is known that apoptosis is involved in the development of DN, but the
mechanisms leading to diabetes-induced podocyte cell death are not fully understood. In this thesis
work we identified SHIP2, PDK1 and CDK2 as novel regulators of podocyte apoptosis, since they
were associated with several features of DN: insulin resistance, podocyte apoptosis and T2D. In
addition, several factors contributed to the changes in SHIP2, PDK1 and CDK2 expression, including
PA, LPS and high glucose. Given the central role of the PI3K-dependent Akt signaling pathway in
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regulating cell survival, we concluded that SHIP2, PDK1 and CDK2 regulate apoptosis in podocytes
by modulating the activity of the PI3K-dependent Akt signaling pathway. Therefore differences in
the expression of these proteins specifically in podocytes separately, or in cooperation might lead to,
or prevent the development of podocyte apoptosis and therefore diabetic kidney complications.
However, many other factors may be involved in the regulation on apoptosis and Akt signaling
pathway in podocytes and thereby additional studies are needed to test this hypothesis.
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